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1 Introduction
1.1 The Immune System
The immune system consists of cells and molecules in order to provide protection (im-
munity) against malignant and infectious diseases.
The immune system is made up of two distinct parts; the innate and the adaptive im-
mune system, with the former being comprised of neutrophils, macrophages, monocytes,
dendritic cells, NK cells, the complement system and cytokines. The latter, adaptive im-
mune system consists of T and B cells, also known as lymphocytes, and antibodies.
Cells of the innate system are capable of detecting pathogens, using only a limited
number of germline-encoded invariant receptors called toll-like receptors (TLRs) [Beut-
ler 2004]. These receptors recognize pathogen-associated molecular patterns (PAMPs),
which are found in a vast array of molecules, for example, lipopolysaccharides (LPS) from
gram-negative bacteria, bacterial flagellin and ssRNA derived from viruses [Akira and
Hemmi 2003]. Proteins produced after activation of innate immune cells include, com-
plement components, defensins, lysozyme, C-reactive protein and cytokines. Cytokines
are small proteins (approximately 25 kDa) that play an important role in cell signaling and
regulation of immune responses. Multiple cell types are capable of releasing and binding
cytokines, which are not only released by a vast range of immune cells such as NK cells,
neutrophils or macrophages, but also by endothelial cells, fibroblasts and other stromal
cells. Maturation, proliferation, activation, apoptosis, and the downregulation of immune
cells are all regulated by different cytokines including Interleukins (IL), Interferons (IFN)
and Tumor-necrosis factor (TNF). In response to antigenic stimulation, macrophages and
dendritic cells secrete IL-1β, IL-6, CXCL8, IL-12 and TNFα. Whereas CXCL8 redirects
immune effector cells to the site of infection, IL-1β, IL-6 and TNFα further induce the
acute-phase response in the liver, and mediate fever.
In fact, the innate immune system reacts similarly to every case of infection, so is
therefore known as non-adaptive. Due to this limited specificity, virus-infected cells and
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malignant cells can easily surpass these defense mechanisms [Drake, Jaffee, and Pardoll
2006].
The acquired immune system is characterized by the ability to recognize different
antigens by specific receptors. During lymphocyte development, gene rearrangement in
V(D)J regions, which encode the antigen-binding sites of lymphocyte receptors, takes
place. As a result, human lymphocyte receptors have a huge variability and can recognize
millions of different antigens. Thus, an acquired immune response is highly specific and
refined over time. Furthermore, repeated contact with a specific pathogen leads to a faster
and stronger immune response due to the development of memory cells that are specific
for the pathogen. The establishment of immunological memory, and the continuous adap-
tation, means that the acquired immune system is also known as the adaptive immune
system [Janeway et al. 2005].
A key feature of the immune system is antigen presentation on the surface of major
histocompatibility complex (MHC) molecules, also known as human leukocyte antigens
(HLA) in humans. All nucleated cells express MHC class I, which presents endogenously,
synthesized and processed peptides on the cell surface. Presented peptides are derived
from antigens such as cytosolic proteins or, as in the case of infection, viral proteins.
Before presentation, endogenous antigens have to undergo processing in the proteasome.
After delivery via transporter associated with antigen processing (TAP), the peptides are
loaded onto the rough endoplasmic reticulum (RER), and eventually peptides comprised
of 8-10 amino acids are presented on the cell surface. [Rammensee, Falk, and Rötzschke
1993]
Dendritic cells, macrophages, monocytes and B lymphocytes, all bear MHC class II
molecules, which are involved in presenting exogenous peptides. After phagocytosis of
bacteria, and their subsequent processing in endosomes, short peptides comprised of 12-
25 amino acids are associated with MHC II molecules, thus forming a MHC II:peptide
complex. The MHC II:peptide complex is then presented on the surface of these spe-
cialized antigen-presenting cells (APCs).The exogenous peptides presented by MHC II
molecules are derived primarily from bacterial proteins, that are taken up and fragmented
into peptides [Watts 1997].
Every lymphocyte has a genotypic surface receptor that binds specifically to its corre-
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sponding antigen. After binding to an antigen, IL-2 stimulated lymphocytes proliferate
and thus a large group of monoclonal cells is formed. So-called clonal selection takes
place in lymphoid organs, such as lymph nodes and the spleen [Burnet et al. 1957]. The
T cell arm of the adaptive immune system is known as cell-mediated immunity, while the
B cell arm is known as humoral immunity.
1.1.1 T Lymphocytes
T cells are a central part of the adaptive immune system, and are involved in cell-mediated
immunity. During T cell development, lymphoid progenitors leave the bone marrow and
migrate to the thymus. Early committed T cells do not express the T cell receptor (TCR),
or either of the costimulatory receptors CD4 or CD8 and are therefore termed double-
negatives (DNs). In the later stages of their maturation, double-positive (DP) T cell pre-
cursors in the cortex exhibit the TCR, and both CD4 and CD8 molecules on their surface.
They then undergo positive selection, which means they are tested for recognition of MHC
molecules. In the medulla, negative selection takes place, which is when the T cells are
tested for recognition of self-antigens. Any T cells with high affinity for self-antigens
undergo apoptosis to prevent them from attacking the host’s own cells. Double-positive
precursors then differentiate further into either CD8+CD4- cytotoxic T cells (CTLs), or
CD4+CD8- T helper cells, before leaving the thymus. As a result, CD4 and CD8 are
mutually exclusive in their expression on T cells in the peripheral blood. Mature T cells
reside in the lymph nodes where CD4+ T cells undergo another step of differentiation.
Stimulation of CD4+ T cells with interleukin 12 (IL-12), secreted by macrophages, in-
duces differentiation into TH1 cells, whereas stimulation with IL-4 induces differentiation
into TH2 cells, and both TGF-β and IL-6 mediate the differentiation of CD4+ T cells into
TH17 cells [Germain 2002]. TH1 cells secrete IFN-γ and thereby activate themselves in
a positive feedback manner, as well as macrophages and CD8+T cells. IL-4 and IL-10,
secreted by TH2 cells, inhibit the activation of TH1 cells. In contrast, TH2 cells secrete IL-
4, IL-5, IL-10 and IL-13 and thus recruit eosinophils and induce activation, proliferation
and differentiation of B cells. IFN-γ secreted by TH1 cells inhibits TH2 cells [Murphy
and Reiner 2002].
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The CD4 and CD8 costimulatory molecules on T cells play an important role in T
cell activation. The TCR on CD4+ T cells recognizes antigen presented by APCs via
MHC II. After antigen recognition, CD4+ T cells are activated and support proliferation
and differentiation of other leukocytes, either by cytokine release or by direct cell-cell
contact. The direct destruction of infected cells by CD4+ T cells is possible, but plays a
subordinate role.
In contrast to CD4+ T cells, CD8+T cells work specifically by the direct killing of
infected and malignant cells. Endogenous peptides, presented by nucleated cells via MHC
class I, are recognized by the TCR on CTLs. After antigen recognition, naive CD8+T
cells are activated to become CTLs, which then release perforin and granzyme in order
to kill infected or malignant cells. Perforin punches a hole in the membrane of the target
cell, allowing the serine protease, granzyme to enter the target cell and induce apoptosis.
Another important defense mechanism involves the expression of Fas ligang (CD95L)
by T cells, and the subsequent induction of apoptosis in target cells. It is evident from
research that the downregulation of MHC I is one of the major mechanisms, that tumor
cells use to avoid destruction by the immune system [Garcia-Lora, Algarra, and Garrido
2003].
Another functionally distinct T cell population is the regulatory T cells (Tregs). Tregs are
of great importance in controlling autoreactive T cells by the release of anti-inflammatory
cytokines, such as IL-10 and TGF-β, and through direct cell-cell contact. It is believed
that Tregs could promote tumor growth as they are preferentially found in the tumor envi-
ronment [H. Y. Wang and R.-F. Wang 2007] [Aggarwal, Das, and Sharma 2016].
All T cells express an antigen receptor, known as the T cell receptor (TCR), with the
vast majority having a TCR consisting of an α chain and a β chain. A small group of T
cells express a TCR that is comprised of a γ and a δ chain, which function as immunoreg-
ulatory cells, and can be found particularly in children and patients that have received a
bone marrow transplant [W. Haas, Pereira, and Tonegawa 1993].
The TCR is associated with some transmembrane proteins that are essential for its sur-
face expression and signal transduction. The most important of these structures is the
CD3 complex, which is comprised of CD3γ,CD3δ, two chains of CD3 and two ζ chains.
As the TCR has no intrinsic signalling activity, the CD3 complex is necessary for sig-
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nal transduction. In the case of TCR binding, phosphorylation of the immune-receptor
tyrosine-based activation motifs (ITAMs) within the CD3 complex eventually leads to
delivery of phospholipase C-γ (PLC-γ). Activation of the PLC-γ, however, requires cos-
timulation of the T cell [Lin and Weiss 2001] [Exley, Terhorst, and Wileman 1991]. Naive
T cell activation requires two signals; the first signal is provided by APCs, which present
antigens via MHC molecules, and the second signal, also known as costimulatory signal,
is given by the interaction of CD28 on naive T cells and B7 (CD80/CD86) on APCs. Dur-
ing antigen presentation, a spatially close contact between T cell and APC is established,
which is referred to as the immunological synapse. Certain activating cytokines that are
present in high doses are also capable of providing a costimulatory signal [Curtsinger
et al. 1999].
The stages of T cell activation can be identified based on the expression of specific
surface molecules on these cells. Only a few hours after receiving the stimulatory and
costimulatory signals, T cells start to express the early activation marker, CD69. Expres-
sion of the C-Lectin, CD69, is sustained for approximately 48 hours, probably providing
a signal that keeps the T cells from leaving the lymph node [Cotner et al. 1983] [Shiow
et al. 2006]. 24 hours after the primary activation of the T lymphocyte, the late activation
marker, CD25, begins to be upregulated. CD25, the alpha chain of the IL-2 receptor, as-
sociates with the constitutively expressed β (CD122) and γ (CD132) chains, thus forming
an IL-2 receptor with high affinity. T cells can now leave the lymph nodes and relocate
to the site of infection, where they eliminate pathogens. Once the antigen is eliminated,
a vast majority of the clonal T cells undergo apoptosis due to lack of stimulatory signals.
However, a small subpopulation of the T cells form memory cells that can easily be reacti-
vated in the case of recurring contact with their specific antigen. The resulting memory T
cell response is much more potent and faster than the primary adaptive immune response
[Sprent and Surh 2002].
Muronomab (OKT3), a monoclonal antibody that is directed against the  subunit of
CD3, was the first antibody to be approved as a therapeutic agent. Binding of muronomab
to CD3 leads to the transient activation of T cells, followed by inactivation and apop-
tosis. Its mode of action made muronomab a candidate for the prevention of transplant
rejection. The activation of T cells is a cause of side effects mediated by muronomab,
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such as cytokine release and systemic inflammatory reactions, therefore, the application
of muronomab must also be accompanied by the application of steroids [Sgro 1995].
1.1.2 B Lymphocytes
After antigen recognition by a B cell, it undergoes somatic to refine antigen binding,
followed by monoclonal proliferation to produce a large number of identical B cells. The
majority of these B cells become short-lived antibody-secreting plasma cells, whereas a
small amount of B cells become memory B cells. Memory cells have a long half-life
and are capable of secreting monoclonal antibodies for a long period of time after the
first antigen-lymphocyte contact took place. Reactivation of existing memory cells is
much more rapid than the initial B cell activation, differentiation and proliferation, which
creates relative immunity after the first contact or after a vaccination. B cells express
surface markers such as CD19, CD20 and CD21, which are crucial for B cell activation
and proliferation [Poe, Hasegawa, and Tedder 2001].
1.1.3 Antibodies
Antibodies, also known as Immunoglobulins (Ig), are proteins, synthesized by plasma
cells, consisting of two light chains (κ and λ) and two heavy chains linked by disulfide
bonds. These bonds allow the antibody to form the characteristic Y-shape, which is cru-
cial for their function. In humans, the five different isotypes of immunoglobulins (Igα,
Igδ, Ig, Igγ ,Igµ), can be distinguished by their different constant domains and specific
properties.
In case of infection, B cells recognize foreign antigens via the B cell receptor (BCR)
and are activated. Subsequent BCR-mediated endocytosis leads to processing of the for-
eign antigen and presentation via MHC class II molecules. A second signal that exerts B
cell activation is provided by the interaction of CD40 on B cells with CD40L on TH2 cells.
As a result, the B cell undergoes activation, affinity maturation, and antibody production.
The first antibody isotype to be produced during the initial humoral immune response is
Igµ. IL-10, IL-4 and CD40L provide signals that then induce an isotype switch from Igµ
to Igγ [Malisan et al. 1996] [Allen et al. 1993].
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Igα provides immunity in the mucous membranes, whereas Igγ and Igµ are preferen-
tially found in the blood. In contrast to the pentameric Igµ, the monomeric Igγ can easily
extravasate towards sites of injury or infection. The latter is a desired feature, which
makes Igγ the most auspicious isotype for therapeutic antibodies. Igγ is a monomer and
has a molecular weight of approximately 150kDa. Furthermore, intact Igγ interacts with
FcRn, which prolongs the immunoglobulin’s half-life significantly [Roopenian and Ak-
ilesh 2007].
The antigen-binding, or Fab, site of an antibody is comprised of the variable domains of
both the light and heavy chains. The complementarity-determining regions (CDR), which
consist of short amino acid sequences, form a paratope that is able to bind specifically to
the epitope of an antigen. The CDR determines the antigen specificity of an antibody, and
its high variability allows the formation of a vast range of human antigen-binding sites.
Possible epitopes include proteins, glycoproteins, and saccharides. The crystallizable, or
Fc, part of an antibody is non-variable and binds to Fc receptors on different immune
cells.
Physiologically, antibodies bind to pathogens, such as bacteria and viruses, and are
able to neutralize pathogens, or at least mark them as exogenous. In addition, antibodies
recruit and activate immune effector cells in a direct or indirect mode of action.
Direct antibody effects are mediated independently of Fc receptor interactions, and are
therefore not isotype-specific. This suggests that F(ab) or F(ab)2fragments, or any other
format bearing an F(ab) part, can sufficiently induce direct antibody effects, such as in-
hibition of ligand-receptor interactions, antagonistic, or agonistic properties. Antibodies
directed against a distinct growth receptor can impede binding of its ligand, thus prevent-
ing a tumor growth signal. Antagonistic antibodies have similar properties when directed
against growth receptors. Agonistic antibodies can provide apoptotic signals to tumor
cells via the CD95 pathway. Aside from that, activation of immune effector cells through
binding of agonistic antibodies (e.g. to CD3) is also feasible.
Indirect properties of antibodies are Fc receptor dependent, and therefore isotype-
specific. Fc dependent mechanisms include complement activation via the classical path-
way, as well as the recruitment and activation of immune effector cells. Complement
activation is restricted to target sites where immobilized Igγ or Igµ molecules are present.
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This prerequisite is needed to avoid complement activation by soluble antibodies. Complement-
dependent cytotoxicity (CDC) is induced by binding of the soluble C1q protein to the Fc
region (CH2 domain) of at least one Igµ or two Igγ molecules. As a result, the complement
cascade is initiated, leading to the opsonization of the antigen by C3b/C4b, chemotaxis,
and formation of the membrane attack complex (MAC). The immune effects that are in-
duced by binding of complement proteins to antibodies, and culminate in death of the
target cell, are termed complement-dependent cellular cytotoxicity (CDCC).
Recruitment and activation of immune effector cells are dependent on the interaction
of the Fcγ regions with specific Fcγ receptors. Five different types of Fcγ receptors have
been characterized, four of which (FcγRI, FcγRIIA, FcγRIIIA, FcγRIIIB) have activating
properties, whereas binding of Igγ to the fifth, FcγRIIB, leads to the inhibition of cellu-
lar activity. To ensure a well-balanced immune response, most immune cells bear both
activating and inhibiting Fcγ receptors. αβT cells do not express Fcγ receptors, whereas
B cells only express the inhibitory FcγRIIB. In contrast, NK cells solely express activat-
ing FcγRIII, which makes them the most important effector cells in antibody-dependent
cellular cytotoxicity (ADCC). After binding of immobilized Igγ to FcγRIII on NK cells
the latter undergoes multimerization which leads to the activation of the NK cell. As a
result, NK cells release perforine and granzyme, and eventually lyse the target cell. It has
been reported that other FcR-bearing cells are capable of inducing ADCC, too. For ex-
ample, γδT cells exhibit FcγRIIIA on their surface and are thus able to induce ADCC in
vitro [Lafont et al. 2001] [Fisher et al. 2015], and although the exact mechanism remains
unclear, neutrophils have been shown to exert ADCC, too [Hernandez-Ilizaliturri et al.
2003] [Egmond and Bakema 2013].
In addition, phagocytosis of Igγ1-coated target cells by macrophages has been ob-
served in vivo, and FcγRIIA seems to play a major role in antibody-dependent cellular
phagocytosis (ADCP) [Oflazoglu et al. 2009].
1.1.4 Leukocyte Adhesion
Chemoattractant cytokines (Chemokines) are small proteins that mediate chemotaxis,
which is the directed migration of immune effector cells. Chemokines mainly act in a
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paracrine manner and allure monocytes, neutrophils and lymphocytes towards the site of
infection [Zlotnik and Yoshie 2000].
Leukocyte migration is a multistep process that always works in a similar pattern, com-
posed of three stages; chemoattraction, adhesion, and diapedesis [Springer et al. 1994].
At first, innate immune cells, such as dendritic cells and macrophages, release TNF-α,
IL-1β, and other cytokines in response to antigen contact. Endothelial cells in close prox-
imity to the source of the chemokines then express selectins. First, preformed P-selectin
(CD62P) from Weibel-Palade bodies is externalized and expressed on the surface of en-
dothelial cells. Shortly after, endothelial cells translate E-selectin (CD62E), and present it
on the surface, thus replacing P-selectin. Selectins are adhesion molecules expressed by
activated endothelium that bind to saccharide derivatives on leukocytes, such as Sialyl-
Lewisx and P-selectin glycoprotein ligand 1 (PSGL-1, CD162). Both P-selectin and
E-selectin are crucial for leukocyte adhesion. Triggered by weak selectin-carbohydrate
interactions, passing leukocytes adhere to endothelial cells. However, these bonds are
constantly interrupted by the shearing forces of blood flow. Ultimately, leukocytes end up
rolling along the endothelium.
The following step of leukocyte migration depends on strong interactions between
heterodimeric integrins on leukocytes, and monomeric intercellular adhesion molecules
(ICAMs) on endothelial cells. An integrin molecule consists of an α chain and a β chain,
with multiple types of both α and β chains being described. A distinct subfamily of in-
tegrins shares a β chain, which is associated with different α chains. Among the most
important integrins necessary for leukocyte migration are leukocyte function antigen 1
(LFA-1, CD11a:CD18 or αLβ2) and macrophage 1-antigen (Mac-1, CR3, CD11b:CD18
or αMβ2). LFA-1 and Mac-1 are expressed on all innate immune cells, while LFA-1 is
additionally expressed on T cells.
ICAMs are membrane-bound molecules that belong to the immunoglobulin superfam-
ily. Both ICAM-1 (CD54) and ICAM-2 (CD102) bind to LFA-1 and Mac-1, with ICAM-2
being more important for extravasation of immune cells through unactivated endothelium.
In addition to endothelial cells, ICAM-1 is expressed on activated leukocytes, and ICAM-
2 is expressed on dendritic cells [Fougerolles et al. 1991].
After leukocyte rolling, activating cytokines induce an upregulation of ICAM-1 on en-
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dothelial cells and conformational changes within LFA-1 on leukocytes. On non-activated
T cells, LFA-1 appears in a flexed state that has only low affinity to ICAM-1 [Kim, Car-
man, and Springer 2003]. TNF-α and chemokines such as CXCL8 in particular, induce
a cytoskeletal transformation of leukocytes that mediates affinity state changes of LFA-1
towards an intermediate-affinity state in an extension shape [Salas et al. 2006]. It has
been shown that activation of the T cell receptor and subsequent CD3 signal transduc-
tion induces similar affinity changes within the LFA-1 molecule [Dustin and Springer
1989] [Van Kooyk et al. 1989].
This in turn allows ICAM-1 to bind to LFA-1 with a 10,000-fold affinity, compared to
the flexed state and thus induces another conformational change towards a high-affinity
state [Shimaoka et al. 2003]. The resulting bond between LFA-1 and ICAM-1 is firm
and allows the leukocyte to start diapedesis, which involves the migration of a leukocyte
between endothelial cells.
1.2 Cancer immunotherapy
In 2000, Hanahan and Weinberg proposed six hallmarks that are shared by all malignant
cells. These include (1) self-sufficiency in growth signals, (2) insensitivity to anti-growth
signals (3) evading apoptosis, (4) limitless replicative potential, (5) sustained angiogen-
esis, and (6) tissue invasion and metastasis. This publication became one of the most
cited cancer research papers ever [Hanahan and Weinberg 2000], and 11 years later, the
same authors published an updated version of the hallmarks, adding two new features: (7)
abnormal metabolic pathways (8) evading the immune system [Hanahan and Weinberg
2011].
Indeed, immune evasion by tumors and immune recognition by cellular and humoral
factors has become a major area of research in recent years. According to the observation
of the cancer papers published since then, it can be stated that cancer immunology and im-
munotherapy is one of the fastest-evolving research fields. There are multiple approaches
that all intend to redirect immune responses against tumor cells, most of which involve T
cells because of their adaptive potential. Strategies include HLA-presented peptide vac-
cinations, chimeric antigen receptors (CAR), cytokine therapy, and in vitro priming of
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autologous immune cells. The most popular category of therapeutic agent is the antibody.
In fact, a vast majority of approved immunological cancer treatments involve antibodies.
1.2.1 Therapeutic Antibodies for Cancer Therapy
In the early 1880s Emil von Behring discovered that the serum of mice, immunized
with diphtheria bacteria can provide a short-term immunity to non-immunized individ-
uals [Von Behring 1890]. At this time, the causative agent to provide humoral immunity
was not yet known. Paul Ehrlich, founder of the concept of chemotherapy, had a vision
in which magic bullets could bind specifically to malignant or infected cells, and thus
destroy them. His dream became a reality less than 100 years later.
The evolution of cancer immunotherapy with antibodies was made possible because
of three milestones in antibody research: identification of antibody structure, hybridoma
technology, and genetic modification of antibodies. The first step to selective cancer
therapy was the elucidation of antibody structure. In 1958, Rodney Porter used papain for
the digestion of immunoglobulins, producing three parts of approximately 50 kDa, with
two of them being identical Fab parts that bind to the same antigen, and the third being an
inert Fc part [Porter 1963] [Porter 1959]. Only three years later, Alfred Nisonoff showed
that the digestion of immunglobulins with pepsin creates two identical Fab fragments.
Furthermore, he created the first bispecific antibody through chemical linkage of two Fab
fragments [Nisonoff and Rivers 1961].
Nevertheless, production of antibodies with predefined specificity remained a formidable
challenge that was successfully met in 1975, when Georges Köhler and Cesar Milstein
published a paper entitled: continuous cultures of fused cells secreting antibody of prede-
fined specificity [Köhler and Milstein 1975]. This publication marked the birth of modern
antibody technology.
In the following years, multiple attempts to produce antibodies for therapeutic appli-
cation were made. Most of the antibodies generated, however, were mouse antibodies
and therefore immunogenic in humans. In fact, these xenogenic antibodies had a short
serum half-life and provoked undesired immune responses [Bertram et al. 1986]. Despite
these disadvantages, the mouse anti-CD3 antibody Muromonab was the first approved
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monoclonal antibody for therapeutic purposes.
To reduce the immunogenicity of mouse antibodies, non-binding regions were later
genetically modified. Thus, the first chimeric (-ximab) and humanized(-zumab) antibod-
ies were produced, in which the constant domains of the antibody were exchanged with
human immunoglobulin sequences, while the mouse antigen-binding regions were not
altered. Murine, chimeric, humanized, and human antibodies are depicted in Fig. 1.1.
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Figure 1.1: Murine, chimeric, humanized, and human Igγ antibodies A Fully murine Igγ anti-
body. B Chimeric antibody comprised of murine variable domains and human constant domains. C
Humanized antibody with murine CDRs. D Fully human Igγ antibody.
Besides their reduced immunogenicity, humanized antibodies also interact more effi-
ciently with human Fcγ receptors, which is another desired feature. Several preclinical
and clinical trials were conducted in the early 1990s to identify promising target antigens
on tumor cells, but most of them did not meet the expectations.
Therapeutic antibodies exert their activity by different modes of action, but by far the
most important mode of action is ADCC, which is induced by interaction of Igγ with
the FcγRIIIA on NK cells. Some antibodies work by blocking the growth receptors on
tumor cells, while others work by the inactivation of soluble molecules that amplify tumor
growth or angiogenesis. A fourth mode of action is the blockade of check-point molecules
on T cells in order to support the anti-tumor activity of those cells.
ADCC. The first anti-tumor antibody ever approved was Rituximab (MabThera®),
in 1998, a chimeric mouse/human anti-CD20 antibody for the treatment of B-cell lym-
phomas [Maloney et al. 1997]. Rituximab combines multiple modes of action and
thus creates a potent anti-tumor response in vivo. The most important mode of action
12
1.2 Cancer immunotherapy
provided by Rituximab is antibody-dependent cell cytotoxicity (ADCC). Furthermore,
complement-dependent cytotoxicity is also induced [Maloney et al. 1997]. Nowadays,
Rituximab is part of major drug regimens for the treatment of lymphomas.
Blocking of growth receptors. In 2000, trastuzumab (Herceptin®) was approved
for the treatment of Her2-positive breast cancer. Trastuzumab, a fully humanized anti-
body, binds to Her2 (Erb2), which is a growth factor receptor expressed on breast cancer
cells. Binding of the Her2 receptor provides a growth-stimulating signal to the tumor
cells, so the binding of an anti-Her2 antibody, means that the tumor cells lack growth
signals and are thus more susceptible to chemotherapy. As with any therapeutic antibody
with an intact Fc binding region, trastuzumab is capable of inducing ADCC [Slikowski
et al. 1999].
Antiangiogenic therapy. Many kinds of tumor cells can provide vasculo-proliferative
signals to endothelial cells. This is to ensure a decent oxygen supply to all tumor cells.
On the one hand, the ability to induce neo-vasculaturization is one of the main malig-
nancy criteria, whereas on the other hand, researchers have found it to be another target
for anti-tumor therapy. In the late 1990s, vascular endothelial growth factor (VEGF) was
characterized as a soluble factor secreted by tumor cells that is capable of inducing prolif-
eration of vessels in the tumor environment. In 2005, Bevacizumab (Avastin®), a human-
ized anti-VEGF antibody was introduced and approved for the treatment of metastasized
colon cancer [Willett et al. 2004].
Checkpoint blockade. A more recently developed approach for antibody-mediated
immunotherapy is checkpoint blockade, which does not involve the interaction of antibod-
ies with Fc receptors. As mentioned earlier, binding of CD28 on T cells to B7 on APCs
provides a second activation signal to T cells, which leads to proliferation. In contrast,
binding of CTLA-4 on T cells to B7 inhibits T cell proliferation. Therefore, blocking anti-
bodies directed against CTLA-4 are able to prolong and reinforce T cell activation. Since
the interaction of CTLA-4 and CD28 marks a checkpoint in the T cell immune cascade,
anti-CTLA-4 antibodies are called checkpoint inhibitors. Ipilimumab(Yervoy®), was the
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first checkpoint inhibitor, and was launched in 2014 as a first line therapy for metastasized
melanoma.
Another immune checkpoint includes the interaction of programmed death-receptor 1
(PD-1) with its ligand. Physiologically, interaction of PD-1 on APCs with PDL-1 on T
cells prevents overwhelming immune reactions. However, tumor cells with a high concen-
tration of PDL-1 on the cell surface can create an immunosuppressive tumor environment,
which promotes tumor growth. Therefore, antibody-mediated blocking of PD-1, enhances
anti-tumor activity of T cells. In 2015, Pembrolizumab (Keytruda®), a humanized anti-
PD-1 antibody, was approved for the treatment of metastasized melanoma.
It was the success of checkpoint inhibitors, among other developments, that prompted
Science to call cancer immunotherapy the most important breakthrough of the year 2013.
This happened because of the therapeutic goals reached by checkpoint inhibitors, such
as anti-CTLA4 or PD-1 antibodies for the treatment of melanoma. Today, antibody ther-
apy is still a promising field, with antibodies and their related products being the fastest
growing class of therapeutic agents [Beck et al. 2010].
Table 1.1: Selected monoclonal anti-tumor antibodies
Antibody Approval Target Cancer type Mode of action
Alemtuzumab 2002 CD52 CLL ADCC, CDC, apoptosis
Bevacizumab 2005 VEGF Colorectal Antivascular
Cetuximab 2004 EGFR Colorectal, Head & neck Anti-growth factor, ADCC
Daratumumab pending CD38 Multiple Myeloma ADCC, CDC
Ipilimumab 2011 CTLA-4 Melanoma Checkpoint inhibitor
Pembrolizumab 2015 PD-1 Melanoma and SCC Checkpoint inhibitor
Rituximab 1998 CD20 NHL ADCC,CDC, apoptosis
Trastuzumab 2000 HER2 Breast ADCC,Anti-growth factor
1.2.2 Bispecific Antibodies in Cancer Therapy
Monospecific antibodies are capable of inducing ADCC and thus promote the killing of
tumor cells by NK cells. However, T cells lack Fcy receptors that allow cells to bind to
the Fc portion of Immunoglobulins. Therefore, monospecific antibodies cannot activate
T cells, which are known to be the most potent immune cells.
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In the 1980s, scientists developed bispecific monoclonal antibodies (BsMAb) 1, that
were able to promote tumor cell killing by T cells, however, there were three prerequisites
that must be met. First, the antibody has to have two binding sites directed against a
tumor-associated antigen (TAA) and a T cell antigen, thus mediating a spatially close
contact between the T cell and the target cell. Second, the T cell binding site must provide
a mitogenic signal to ensure on-target T cell activation. For example, binding of specific
antibodies to the TCR/CD3 complex provides a strong and persistent activation signal to
T cells. Finally, T cell activation must be limited to the tumor site. There should be no
off-target activation, this prerequisite is referred to as target cell restriction.
In 1985, Staerz et al. showed that monoclonal antibodies directed against the T cell
receptor have a mitogenic effect on CTL clones when coupled to different cell types.
Furthermore, they coupled two monoclonal antibodies with SDPD, a heterobifunctional
crosslinker. One of the two monoclonal antibodies was directed against the Thy-1.1 al-
loantigen on leukemic cells and another one was directed against the TCR (T1). The
resulting full-size antibody heteroconjugates - as they called them - induced a highly ef-
ficient CTL response in vitro. Specific lysis of TAA+ tumor cells by mouse CTLs was
observed [Staerz, Kanagawa, and Bevan 1985].
In the same year, Perez et al. created heteroconjugates composed of an anti-human
CD3 binding site (OKT3), and an anti-murine Kk alloantigen binding site. Four different
anti-HLA-DPw2 CTL clones were used as effector cells against murine Kk+ tumor cells.
The formation of multicellular tumor-CTL conjugates and subsequent target cell lysis was
observed. As human CTL clones showed efficient lysis of xenogenic murine tumor cells,
it became clear that CD3 targeting with bispecific antibodies is independent of MHC
presentation. Perez et al. suggested the use of different conjugates containing Fc regions
to activate lymphocytes as well as NK cells and macrophages [Perez et al. 1985].
Only two years later, Staerz et al. showed the effective lysis of influenza virus-infected
cells in vivo after the application of a bispecific antibody, composed of anti-TCR and
anti-hemagglutinine binding sites [Staerz, Yewdell, and Bevan 1987].
1In the context of this thesis, the abbreviation BsMAb(Bispecific monoclonal antibody) - if not otherwise
specified - refers to bispecific antibodies with a CD3/TCR stimulating binding site and another binding
site directed against a tumor associated antigen.
15
1 Introduction
In 1986, Jung et al. showed that not only mouse CTL clones, but also human peripheral
blood mononuclear cells (PBMCs) can be activated by hybrid antibodies. As a result, hu-
man Raji and M21 tumor cells coated with antibodies were killed effectively by PBMCs
preincubated with OKT3. Lysis could be stopped by the excess addition of the mono-
clonal antibody, OKT3. The bispecific antibodies that Jung et al. used were composed of
the monoclonal anti-CD3 antibody OKT3 and different antibodies directed against TAA.
Chemical linkage with SPDP was used to generate the hybrid antibodies [Jung, Honsik,
et al. 1986].
In 1988, Jung et al. suggested that it may be preferable to use F(ab’)2 fragments rather
than intact antibodies to rule out any effects mediated by binding of conjugates to Fcγ
receptors in vivo [Jung and Müller Eberhard 1988] [Jung, Freimann, et al. 1991].
As an alternative to chemical linkage, generation of bispecific antibodies can be real-
ized by the fusion of two different hybridoma cell lines. The resulting cell line secretes
both pristine monospecific antibodies, as well as bispecific antibodies [Staerz and Bevan
1986].
In the years that followed, advances in recombinant DNA technology allowed the gen-
eration and improved production of bispecific antibody molecules. On the one hand,
humanization and miniaturization of bispecific antibodies reduced the immunogenicity
markedly. However, on the other hand, recombinant DNA technology has allowed the
generation of engineered antibodies in new formats.
An important building block for the generation of recombinant BsMAbs, is the so-
called single chain fragment (scFv). A scFv is composed of the VH and the VH domain
of an antibody, with both of them being included in a single polypeptide chain and joined
with a peptide linker. Combination of two or more scFv, allows the generation of bi-,
tri- and multispecific antibodies. Linkage of two scFv in one polypeptide chain results
in formation of the bispecific single chain scFv format (bssc, also termed bispecific T-
cell engager (BiTE)), whereas heterodimerization of two scFv peptide chains creates a
BsMAb in the single chain diabody (scDiabody) format [Holliger, Prospero, and Winter
1993] [Mack, Riethmüller, and Kufer 1995]. Different bispecific antibody formats are
depicted in Fig. 1.2.
BsMAb in both formats are small (approximately 55 kDa) and have a very short serum
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half-life due to impaired interaction with FcγRn [Müller and Kontermann 2010]. BsMAb
in formats that resemble the structure of Igγ more closely could exhibit a longer serum
half-life. Durben et al. established a FLT3×CD3 BsMAb in a new Fabsc format [Durben
et al. 2015].
X
O
VL
CL
CH2
VH
VH
CH1
VL
VL-L1-VH-L2-VH-L1-VL
A           B
Figure 1.2: Bispecific antibody formats A Fabsc format. The antibody is comprised of a Fab part
derived from an antibody directed against a TAA and a single chain fragment derived from an antibody
directed against CD3. X indicates replacement of the amino acid cystein in order to avoid dimerization.
Replacement of several amino acid residues in the CH2 domain in order to prevent binding to Fc
receptors is depicted as O. B Bssc/BiTe format. The single chain antibody is comprised of two VL
and two VH parts derived from two antibodies, with one of them being directed against a TAA and
the other against CD3. L1 indicates a glycine-serine linker, and L2 indicates a amino acid sequence
derived from the elbow fragment of human Igγ1.
1.2.3 Characteristics of Bispecific PSMA x CD3 Antibody
NP-CU
All experiments included in this thesis were conducted using a bispecific PSMA×CD3
antibody (NP-CU) in a new recombinant Fabsc format. NP-CU was generated and char-
acterized by Dipl.-biol. Fabian Vogt at the Department of Immunology in Tübingen. The
structure of Fabsc constructs is more similar to the mutual Igγ structure than the estab-
lished bssc format. It consists of a Fab region, a linker CH2 domain with genetic mod-
ifications to impair FcR-binding, and a single chain antibody with a second specificity.
In contrast to the Fab-derived format described by Schoonjans et al. the Fabsc-format
described here contains a CH2-domain separating the two specificities in order to reduce
undesirable interactions between them [Durben et al. 2015] [Schoonjans et al. 2000].
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The PSMAxCD3 Fabsc antibody was composed of the PSMA-antibody J591 (Fab) and
the CD3-antibody UCHT1 (single chain) [H. Liu et al. 1997] [Beverley and Callard
1981].
1.2.4 Current Issues in Bispecific Antibody Therapy
Dose Limitation
Recently, the bispecific CD19xCD3 antibody Blinatumomab was approved for the treat-
ment of CD19+ acute lymphoblastic lymphoma (ALL) after showing efficacy in killing
tumor cells [R. Bargou et al. 2008]. Blinatumomab is applied as a continuous infusion
due to its short serum half-life of approximately 2.11 hours. The suggested daily dose for
patients who weigh at least 45kg is 9µg/day on days 1-7 and 28µg/day on days 8-28. At
these clinical doses for the treatment of relapsed/refractory ALL, the mean steady-state
serum concentration was 211 pg/mL and 621 pg/mL, respectively [AMGEN 2015].
Notably, this concentration is 10,000 fold lower than those achieved with monospecific
antibodies [Adams and Weiner 2005].
One should recognize that this exceptionally low serum concentration does not provide
saturation of the target antigen at the tumor cell surface.Dense coating of tumor cells by
bispecific antibodies can effectively induce tumor cell killing, therefore, it is believed that
higher concentrations would greatly enhance the anti-tumor effect of bispecific antibodies.
In fact, it is widely held that serum concentrations of the BsMAb blinatumomab are sub-
optimal.
However, severe dose-dependent side effects seen in clinical studies do not allow the
application of higher doses [Topp et al. 2011] [Klinger et al. 2012]. Two major problems
have been observed repeatedly in clinical trials with BsMAb: Lymphocyte drop, and
cytokine release syndrome, with the latter being more severe and thus life-threatening.
Cytokine Release Syndrome after treatment with BsMAbs
Severe systemic side effects upon the clinical application of bispecific antibodies have
been observed during previous clinical trials.
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For example, in 1994, Kroesen et al. published a phase 1 study of intravenously applied
bispecific antibody in renal cell cancer patients (n=14). The antibody used in this study
was a (Fab’)2 bispecific antibody that was generated by hybrid-hybridoma technology.
The resulting quadroma, produced a fusion protein composed of an anti-CD3 antibody
(Igγ3) and an anti-epithelial glycoprotein 2 (EGP2) antibody (Igγ1). All patients had
received prior subcutaneous IL-2 treatment that was maintained during the clinical trial.
During the clinical trial, patients received BIS-1 (Fab’)2 at doses of 1, 3, and 5 µg per
kg body weight. Acute toxicity was observed in 2 out of 4, and 5 out of 5 patients that
received 3 and 5 µg per kg, respectively. The observed symptoms included chills, periph-
eral vasoconstriction with increased diastolic tension, dyspnea, and fever. The maximal
tolerated dose (MTD) was 5 µg per kg. Patients who received BIS-1 at 5 µg per kg were
tested for elevated TNF-α and IFN-γ levels. In fact, TNF-α production increased up to
180 pg/ml and IFN-γ levels reached 12 U/ml. Peak levels of TNF-α and IFN-γ were
observed 2 and 3 hours after the start of the application. After 24 hours, cytokine levels
had returned to normal [Kroesen et al. 1994].
In 1993, Tibben et al. conducted a study of intravenously applied BsMAb in ovar-
ian carcinoma patients (n=5). The tested antibody was a (Fab’)2 BsMAb named OC/TR.
OC/TR consists of two Igγ1 fragments, with binding sites to CD3 and a tumor-associated
folate-binding protein. The BsMAb was obtained after fusion of the MOv18 hybridoma
with spleen cells from a BALB/c mouse, immunized with a human T cell clone. Dur-
ing the clinical trial, the first patient received an intravenous infusion of 1mg BsMAb.
Unfortunately, the patient observed grade 3-4 adverse events including headache, fever
with hypotension, fatigue, chills, nausea, vomiting, and diarrhea [J. Tibben et al. 1993].
Due to this toxicity, patients 2-4 were treated at doses of 0.1 and 0.2 mg, however, simi-
lar adverse events were observed, and symptoms had to be treated with paracetamol and
metoclopramide, resulting in the termination of the study.
Cytokine analysis showed increased levels of IL-2, TNF-α and IFN-γ in the patient’s
serum. Whereas elevated serum levels of IL-2 were only observed in patients that received
higher doses (1mg or 0.2mg), all patients showed high levels of TNF-α and IFN-γ. Peak
levels of all cytokines were observed 2 hours after infusion, but they normalized at 24h
after infusion. Serum levels of IL-2 and TNF-α seemed to correlate well with clinical
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symptoms [J. G. Tibben et al. 1996].
In 2011, an open-label, multicenter, single-arm, phase 2 clinical study with the bssc
CD3×CD19 BsMAb blinatumomab(MT103) was conducted, including 21 patients suf-
fering from minimal residual (MRD) B-lineage ALL. Blinatumomab was applied as a
continuous intravenous infusion for four weeks at a dose of 15g/m2/24 hours. The re-
sulting serum concentration was 0.6 ng/ml. This exceptionally low dose makes the thera-
peutic effect all the more remarkable. During this trial, transient peaks of cytokines could
be observed in the majority of patients. Cytokine release started 2 hours after the first
infusion, and was limited to 48 hours. Out of 21 patients, six patients showed an increase
in IL-6 plasma levels only, four patients in IL-6 and IFN levels, two patients in IL-6, IL-2
and IFN levels, and one patient in IL-6, IFN and TNF-α levels. Despite the very low anti-
body serum levels, patients experienced fever, chills, decrease in blood immunoglobulin,
and hypokalemia [Topp et al. 2011].
The in-vivo administration of T cell recruiting bispecific antibodies led to cytokine
release in past experiments. It is believed that off-target effects play a mayor role in the
development of cytokine release syndromes.
Off-target activation can be induced via two different mechanisms: (1) The tumor-
associated antigen (TAA) is not entirely tumor specific. Thus, the BsMAb binds to healthy
cells expressing TAA. Subsequent T cell binding and activation leads to cytokine release
and killing of TAA+cells. This, however, is not really off-target activation in a strict
sense, as it is still induced by TAA+cells. However, the depleted cells are not tumor cells
and therefore ’off-target’ means ’off-tumor’ here. Blinatumomab obviously suffers from
this kind of off-target T cell activation, since the target antigen, CD19 recognized by this
molecule is not only expressed on human cells of the B-ALL lineage, but also on normal
B cells.
(2) Binding of BsMAb via its CD3 binding site leads to T cell activation, independent
of target cells. This means, BsMAb-induced T cell activation is not - as it should be
- target cell restricted. This type of off-target activation takes place in the absence of
TAA+cells.
Off-target T cell activation, upon application of BsMAb may promote cytokine release
that significantly limits safely applicable doses. It is therefore of utmost importance to
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understand and prevent this side effect.
Another phenomenon that was repeatedly observed upon application of BsMAb was a
drop in lymphocyte counts within the peripheral blood.
Lymphocyte drop
Conductors of a phase 1 study of intravenously applied bispecific antibody in renal cell
cancer patients, observed lymphopenia in various patients. They described a rapid re-
duction in the number of PBMCs in the peripheral blood during the infusion of 5 µg per
kg BsMAb. Whereas the number of granulocytes showed no consistent changes, mono-
cyte and lymphocyte counts were significantly reduced, two hours after the start of the
infusion.
Lymphocyte subset analysis showed a preferential reduction in the percentage of LFA-
la-bright and HLA-DR+ cells within the CD8+ lymphocyte population [Kroesen et al.
1994].
Another clinical study with ovarian cancer patients showed similar effects. Approxi-
mately 30 minutes after infusion, lymphocyte counts in almost all patients dropped. How-
ever, they showed a full recovery, when they were analyzed 48 hours later [J. G. Tibben
et al. 1996].
During a phase 2 clinical trial in 2011, blinatumomab was applied to 21 ALL patients
as a continuous intravenous infusion for four weeks at a dose of 15g/m2/24 hours. The
resulting serum concentration was 0.6 ng/ml.
Eleven out of the 21 patients experienced grade 3 or 4 adverse events, with lymphope-
nia being the most frequent event (7 out of 21 patients). However, as with the previous
study, every case of lymphopenia resolved within 48 hours. Granulocytopenia and throm-
bocytopenia were also observed, but only in one patient [Topp et al. 2011].
Clinical studies performed since the 1990s have shown a transient lymphocyte drop
after administration of a T cell-activating bispecific antibody. However, the lymphocyte
count was restored after a few hours, suggesting a transient adhesion of T cells to the
endothelium and possible migration.
Transient lymphopenia by itself does not seem to be a severe side effect, however,
lymphopenia could play an important role in the early development of cytokine release,
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since T cell adhesion promotes T cell activation [Hynes 1992]. It is possible that blocking
T cell adhesion could inhibit overwhelming cytokine release, thus allowing application of
BsMAb at higher dose levels.
The Link Between Cytokine Release and Lymphocyte Drop
Molema et al. observed both cytokine release and lymphocyte drop during their clinical
study with bispecific antibodies [Kroesen et al. 1994]. In-vitro studies showed that the
application of bispecific antibodies leads to the upregulation of ICAM-1 and other ad-
hesion molecules on endothelial cells, which results in an increased adhesion of T cells
to endothelial cells [Molema et al. 2000]. As mentioned previously, binding of LFA-1
(CD18:CD11a) to ICAM-1 (CD54) induces mitogenic signals in T cells. This suggests
that increased adhesion of T cells, as observed in patients after application of bispecific
antibodies, contributes to off-target T cell activation.
Prevention of Cytokine Release Syndrome
Prophylactic administration of steroids before the application of bispecific antibodies is
performed to prevent cytokine release [Brandl et al. 2007] [Mori et al. 2015] [AMGEN
2015]. However, corticosteroids are one of the most potent immunoinhibitory drugs in
humans, and work through a variety of different mechanisms [Claman 1972]. It is possible
that steroids diminish the therapeutic potential of bispecific antibodies.
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1.3 Aim and Objective of this Thesis
Severe systemic side effects after administration of T cell-activating bispecific antibodies
are well-known phenomena. Maximal tolerated doses of recently approved bispecific
antibodies remain sub-optimal in terms of saturation of the tumor-associated antigen. In
contrast to the importance of this phenomenon, only a few research projects have been
conducted in an attempt to fully understand the involved mechanisms. The work described
in this thesis aims at a better understanding of bispecific antibody-mediated off-target T
cell activation. To this end, the costimulatory effects of endothelial cells (HUVECs), and
some certain lymphoid cells, designated stimulating bystander cells (SBCs), have been
further explored. A special focus lies in the characterization of molecules mediating the
interaction of T cells and SBCs with the intention to interfere with this interaction, such
that undesired off-target T cell activation is diminished.
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2 Material and Methods
2.1 Material
2.1.1 Equipment
Cell harvester Inotech Biosystems International, Inc. Rockville, USA
Centrifuge 5417C Eppendorf AG, Hamburg, GER
Centrifuge Heraeus Biofuge fresco Thermo Electron, Waltham, USA
Centrifuge Heraeus Megafuge 1.0 Thermo Electron, Waltham, USA
Centrifuge Sorvall RC5C Plus Thermo Fisher Scientific GmbH, Schwerte, GER
Clean bench 3F120-II GS Integra Biosciences GmbH, Fernwald, GER
Clean bench 3F150-II GS Integra Biosciences GmbH, Fernwald, GER
ELISA reader Spectra Max 340 Molecular devices, Ismaning, GER
FACS Calibur BD Biosciences, Heidelberg, GER
FACS Canto II BD Biosciences, Heidelberg, GER
Freezer Colora E80 Colora Messtechnik GmbH, Lorch, GER
Gammacell 1000 Elite MDS Nordion, Ottawa, CAN
Incubator APT.line CD(E6) Binder GmbH, Tuttlingen
Incubator Heraeus function line Thermo Electron, Waltham, USA
MicroBeta2 Counter Perkin Elmer, Rodgau, GER
Microscope Zeiss IM 35 Carl Zeiss AG, Oberkochen, GER
Microscope Axiovert 25 Carl Zeiss AG, Oberkochen, GER
Multichannel pipette Abimed GmbH, Langenfeld, GER
Nanodrop™1000 Thermo Fisher Scientific GmbH, Schwerte, GER
pH-meter Seven Multi Mettler-Toledo GmbH, Giessen, GER
Pipetboy acu Integra Biosciences GmbH, Fernwald, GER
Pipettes DV1000, DV200, DV100,
DV20, DV10, DV2
Abimed GmbH, Langenfeld, GER
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Refrigerator Liebherr Premium Liebherr Hausgeräte GmbH, Ochsenhausen, GER
Scale PT600 Sartorius AG , Göttingen, GER
Vortex VF2 IKA-Werke GmbH& Co. KG, Staufen, GER
Water bath Julao 19 Julabo Labortechnik GmbH, Seelbach, GER
xCELLigence RTCA Roche Diagnostics GmbH, Mannheim, GER
2.1.2 Glass and plastic supplies
15ml Falcon BD Biosciences, Heidelberg, GER
50ml Falcon Greiner Bio One, Frickenhausen, GER
Cannulas Microlance 3 BD Biosciences, Heidelberg, GER
Cell Culture Flasks 25 cm2, 75 cm2,
175 cm2
Greiner Bio One, Frickenhausen, GER
Cell culture plates 6 well BD Biosciences, Heidelberg, GER
Cell culture plates 96 well Greiner Bio One, Frickenhausen, GER
Cell strainer 40um BD Biosciences, Heidelberg, GER
Centrifuge beaker Thermo Fischer Scientific GmbH, Schwerte, GER
Centrifuge tubes Thermo Fischer Scientific GmbH, Schwerte, GER
Combitips Eppendorf AG, Hamburg, GER
Cryo vials 2ml Greiner Bio-One, Frickenhausen, GER
Dialysis Tube Visking Type 27/32 Carl Roth GmbH & Co. KG, Karlsruhe, GER
ELISA Plates Nunc Maxisorp F-
Bottom, 96well
Nunc GmbH & Co. KG, Langenselbold, GER
E-Plate Roche Diagnostics GmbH, Mannheim, GER
Eppendorf Cups 1,5ml, 2ml Eppendorf AG, Hamburg, GER
Flow cytometry Tubes Sarstedt AG & Co., Nürmbrecht, GER
Freezing Container Mr. Frosty® Thermo Fischer Scientific GmbH, Schwerte, GER
Glass Beaker Schott AG, Mainz, GER
Glass bottles 1l, 2l Schott AG, Mainz, GER
Gloves Nitrile Paul Hartmann AG, Heidenheim, GER
Neubauer counting chamber Brand GmbH & Co KG, Weinheim, GER
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Parafilm Pechiney Plastic Packaging, Chicago, USA
Pipette tips 10, 20, 200, 1000ul Starlab GmbH, Ahrensburg, GER
Pipette tips 100ul Biozym Scientific GmbH, Hessisch Oldendorf, GER
Plastic Beaker Vitlab GmbH, Großostheim, GER
Printet Filtermats A Perkin Elmer, Rodgau, GER
Reagents Reservoir Costar Sigma-Aldrich Chemie GmbH, München, GER
Safety-Multifly ® Set 21G Sarstedt AG & Co., Nürmbrecht, GER
Serological pipettes 2ml BD Biosciences, Heidelberg, GER
Serological pipettes 5,10,25,50ml Corning Inc., Corning, USA
Single-use syringes 5,10,20,50ml BD Biosciences, Heidelberg, GER
Syringe filter units 0,22um, diame-
ter 4, 13mm
Millipore, Schwalbach, GER
2.1.3 Chemicals and reagents
Biocoll separating solution Biochrom GmbH, Berlin, GER
β-mercaptoethanol Carl Roth GmbH & Co. KG, Karlsruhe, GER
Bovine serum albumin (BSA) Carl Roth GmbH & Co. KG, Karlsruhe, GER
Dimethyl sulfoxid (DMSO) Merck KGaA, Darmstadt, GER
Ethanol Merck KGaA, Darmstadt, GER
Ethylenediaminetetraacetic acid Sigma-Aldrich Chemie GmbH, München, GER
[methyl-3H] Thymidine Hartmann Analytik GmbH, Braunschweig, GER
Phytohemagglutinin (PHA-L) Sigma-Aldrich Chemie GmbH, München, GER
rIFNgamma Pan-Biotech GmbH, Aidenbach, GER
Sodium azide Merck KGaA, Darmstadt, GER
Trypan blue 0,4% Sigma-Aldrich Chemie GmbH, München, GER
Tween® 20 Merck KGaA, Darmstadt, GER
ULTIMA Gold™ liquid scintilla-
tion cocktail
PerkinElmer, Rodgau, GER
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2.1.4 Buffers and media
Supplements for buffers
Dulbecco’s Phosphate buffered Saline (DPBS) Life Technologies, Darmstadt, GER
RPMI 1650 Medium Life Technologies, Darmstadt, GER
Iscove’s Modified Dulbeccos’s Medium Lonza Group Ltd, Basel, CH
Sodium Pyruvate Biochrom GmbH, Berlin, GER
L-Glutamine Lonza Group Ltd, Basel, CH
MEN non essential amino acids Biochrom GmbH, Berlin, GER
Penicilline/Streptomycine Sigma-Aldrich Chemie GmbH, München, GER
b-mercapto Ethanol Carl Roth GmbH & Co. KG, Karlsruhe, GER
Fetal Calf Serum PAA Laboratories GmbH, Pasching, A
Endothelial Cell Growth Medium 2 PromoCell, Heidelberg, GER
Accutase Sigma-Aldrich Chemie GmbH, München, GER
Trypsin-EDTA PAA Laboratories GmbH, Pasching, A
Cell culture media
R
¯
PMI 1640 Complete Medium RPMI 1640 Medium
10% (v/v) FCS (heat inactivated at 56 °C for
one hour)
1 mM Sodium Pyruvate
1x MEM non-essential amino acids
100 U/ml Penicilline
100 µg/ml Streptomycine
50 µM β-mercaptoethanol
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I
¯
MDM Complete Medium IMDM Medium
10% (v/v) FCS (heat inactivated at 56 °C for
one hour)
1mM Sodium Pyruvate
1x L-Glutamine
1x MEM non-essential amino acids
100 U/ml Penicilline
100 µg/ml Streptomycine
50 µM β-mercaptoethanol
E
¯
ndothelial Cell Growth Complete Medium Endothelial Cell Growth Medium 2
100 U/ml Penicilline
100 µg/ml Streptomycine
F
¯
reezing Medium 90% (v/v) Fetal Calf Serum
10% (v/v) Dimethyl sulfoxide
Cell counting and viability staining
Trypan-Blue Solution 0,05% (v/v) Trypan-Blue
Tuerk Solution Sigma-Aldrich Chemie GmbH, München, GER
Magnetic activated cell sorting
MACS buffer DPBS
0.5% (v/v) Bovine serum albumin
2mM EDTA
Flow cytometry
7AAD viability staining buffer BioLegend GmbH, Fell, GER
FACS Flow DPBS
0,02% (w/v) Sodium azide
1% (v/v) Fetal Calf Serum
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ELISA buffer
Blocking solution 10% (v/v) BSA
in H2O bidest
Washing buffer 0,05% Tween-20
in PBS
Dilution buffer 10% (v/v) BSA
in H2O bidest
Stop solution 1M H3PO4
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2.1.5 Antibodies
Conjugated antibodies
Antigen Clone Species Conjugate Origin/Purchase
Human CD8 RPA-T8 Mouse FITC Biolegend, Fell, GER
Human CD69 FN50 Mouse PE Biolegend, Fell, GER
Human CD54 HCD54 Mouse PE Biolegend, Fell, GER
Human CD45 2D1 Mouse AmCyan BD Biosciences, San Jose, USA
Human CD4 OKT4 Mouse PacificBlue Biolegend, Fell, GER
Human CD34 581 Mouse APC/Cy7 Biolegend, Fell, GER
Human CD33 WM53 Mouse APC Biolegend, Fell, GER
Human CD14 HCD14 Mouse PE/Cy7 Biolegend, Fell, GER
Human CD117 A3C6E2 Mouse PE/Cy7 Biolegend, Fell, GER
Human CD105 43A3 Mouse APC Biolegend, Fell, GER
Human CD8 OKT8 Mouse FITC homemade
Isotype Control MOPC-21 Mouse FITC Biolegend, Fell, GER
Isotype Control MOPC-21 Mouse PE Biolegend, Fell, GER
Isotype Control MOPC-21 Mouse PacificBlue Biolegend, Fell, GER
Isotype Control MOPC-21 Mouse APC/Cy7 Biolegend, Fell, GER
Isotype Control MOPC-21 Mouse APC/Cy7 Biolegend, Fell, GER
Isotype Control MOPC-21 Mouse PE/Cy7 Biolegend, Fell, GER
Human IgG, Fcgamma spec Goat RPE Jackson ImmunoResearch, West Grove, USA
Mouse IgG+IgM Goat RPE Jackson ImmunoResearch, West Grove, USA
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Unconjugated antibodies
Name/Clone Antigen Species Isotype Origin/Purchase
136726 human CD275 (LICOS) Mouse Igγ1 Biolegend, Fell, GER
11C3.1 human CD252 (OX40L) Mouse Igγ1 Biolegend, Fell, GER
2D10 human CD80 Mouse Igγ1 Biolegend, Fell, GER
3.9 human CD11c Mouse Igγ1 Biolegend, Fell, GER
4G7 human CD19 Mouse Igγ1 M. Hofmann, Tübingen, GER
4G8 human FLT3 Mouse Igγ1 H.J. Bühring, Tübingen, GER
4G8 SDIEM human FLT3 Human Igγ1 M. Hofmann, Tübingen, GER
5C3 human CD40 Mouse Igγ1 Biolegend, Fell, GER
Bu15 human CD11c Mouse Igγ1 Biolegend, Fell, GER
CBR-1C2/2 human CD102 (ICAM-2) Mouse Igγ1 Biolegend, Fell, GER
CBRM1/5 human CD11b Mouse Igγ1 Biolegend, Fell, GER
DREG-56 human CD62L Mouse Igγ1 Biolegend, Fell, GER
Flebo Gamma polyclonal human Grifols International S.A.
HA58 human CD54 (ICAM-1) Mouse Igγ1 Biolegend, Fell, GER
HAE-1f human CD62E Mouse Igγ1 Biolegend, Fell, GER
HCD54 human CD54 (ICAM-1) Mouse Igγ1 Biolegend, Fell, GER
HI111 human CD11a Mouse Igγ1 Biolegend, Fell, GER
ICRF44 human CD11b Mouse Igγ1 Biolegend, Fell, GER
Infliximab human TNF-a Mouse/Human Igγ1 Janssen Biotech Inc., Horsham, USA33
IT2.2 human CD86 Mouse Igγ1 Biolegend, Fell, GER
N19-CU N297Q human CD19, hum. CD3 Mouse/Human bsFab M.Durben, Tübingen, GER
NFAP-CU N297Q human FAP, hum. CD3 Mouse/Human bsFab F. Vogt, Tübingen, GER
NF-CU N297Q human FLT3, hum. CD3 Mouse/Human bsFab M. Durben, Tübingen, GER
NG-CU N297Q human GD2, hum. CD3 Mouse/Human bsFab D. Schmiedel, Tübingen, GER
NM-CU N297Q human CSPG4, hum. CD3 Mouse/Human bsFab L. Große-Hovest, Tübingen, GER
NP-CU N297Q human PSMA, hum. CD3 Mouse/Human bsFab F. Vogt, Tübingen, GER
RPA-2.10 human CD2 Mouse Igγ1 Biolegend, Fell, GER
TKS-1 human CD137L (4-1BBL) Mouse Igγ1 Biolegend, Fell, GER
TS1/18 human CD18 (Integrin beta2) Mouse Igγ1 Biolegend, Fell, GER
TS2/4 human CD11a Mouse Igγ1 Biolegend, Fell, GER
TS2/9 human CD58 Mouse Igγ1 Biolegend, Fell, GER
UCHT-1 human CD3 - epsilon Human IgG2a L. Große-Hovest, Tübingen, GER
Tocilizumab human IL-6 Mouse/Human Igγ1 Hoffmann-La Roche AG, Basel, CH
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2.1.6 Cell lines
Name Type Origin/Purchase Literature
HUVEC Human umbilical vein endothelial cells Promocell, Heidelberg, GER Jaffe et al. 1973
JY Human B lymphoblastoid leukemia European Collection of Cell Cultures Swaroop and Xu 1993
LN-18 Human glioblastoma M. Weller, Tübingen, GER Diserens et al. 1981
NALM-16 Human acute lymphoblastic leukemia DMSZ GmbH, Braunschweig, GER Kohno, Minowada, and Sandberg 1980
SKMel63 Human malignant melanoma B. Gückel, Tübingen, GER J. Fogh, J. M. Fogh, and Orfeo 1977
SKW 6.4 Human B cell lymphoma P.H. Krammer, Heidelberg, GER Saiki and Ralph 1983
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2.2 Methods
2.2.1 Cell Biology Methods
Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
Freshly drawn, heparinized blood from healthy donors was diluted 1:1 with PBS. 25 ml
of diluted blood was layered over 14 ml of Biocoll Separating Solution in a sterile 50 ml
Falcon tube and centrifuged at 360× g for 30 min, at 25°C, without brake. Subsequently,
the interphase (buffy coat) was collected, which included the peripheral blood mononu-
clear cells (PBMCs). The cells were washed twice with PBS for 10 minutes at 25 °C (first
run at 300×g, then at 200×g) to remove traces of Biocoll solution and the cell pellet was
resuspended in RPMI 1640 Complete Medium.
Culture of Tumor Cell Lines
All tumor cell lines were cultured at 37°C, 5% CO2, and 90% relative humidity in 75cm2
cell culture flasks, containing 12 ml of RPMI 1640 complete medium.
Culture of PBMCs
PBMCs were cultured at 37°C, 5% CO2, and 90% relative humidity in 75cm2 cell culture
flasks, containing 12 ml of RPMI 1640 complete medium.
Culture of Human Umbilical Vein Endothelial Cells (HUVECs)
HUVECs were cultured at 37°C, 5% CO2, and 90% relative humidity in 75cm2 cell cul-
ture flasks, containing 10 ml of Endothelial Cell Growth Complete medium.
Culture of Antibody-Producing Transfectants
Antibody-producing transfectants were cultured at 37°C, 5% CO2, and 90% relative hu-
midity in 175cm2 cell culture flasks, containing 50ml of IMDM complete medium.
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Harvesting of Adherent Cells
To harvest adherent cells (e.g., 22RV1, HUVECs, LN-18), the cell culture medium was
carefully removed from the flask. Then, cells were rinsed once with 10 ml of PBS. Af-
terwards, 1 ml of Accutase cell detachment solution was added, and the flask was kept in
an incubator for 5 minutes Detachment was confirmed by microscopy, and the cells were
resuspended in cell culture medium and removed from the flask.
Harvesting of Non-Adherent Cells
To harvest non-adherent cells, culture flasks were carefully agitated. Detachment was
confirmed by microscopy, and the cell suspension was removed from the flask.
Cryopreservation of Cells
After harvesting, the cell suspension was centrifuged for 10 minutes at 310×g and the
supernatant was discarded. The cell pellet was resuspended in 1.5 ml of freezing medium,
and placed in a cryo tube. Tubes were immediately put into a Mr. Frosty™ freezing
container and stored for at least 12 hours in a -80 °C freezer, in order to secure steady
freezing of approximately 1 K per hour.
Thawing of Cryopreserved Cells
25 ml of cell culture medium was prepared in a 50 ml Falcon tube and warmed to 37
°C. Afterwards, cryo tubes containing preserved cells were thawed in a water bath at 37
°C. The cell suspension was transferred into the Falcon tube containing the prewarmed
medium, and immediately centrifuged for 10 min at 310×g. The cell pellet was resus-
pended in 12 ml of cell culture medium. Viability was assured microscopically, 24 hours
later.
Cell Counting and Viability Staining of Cells
40µl of cell suspension and 40µl of 0.05% Trypan blue solution were mixed together and
pipetted into a Neubauer chamber. Only unstained, viable cells were counted. The cell
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number was determined using the following equation:
cells/ml = counts per quadrant × chamber constant(104)× dilution factor
Inactivation of Tumor Cells
Tumor cells were irradiated at a dose of 120 Gy using a GammaCell irradiation chamber,
containing 137Caesium, in order to prevent them from proliferation during T cell prolifer-
ation assays.
2.2.2 Analytical Methods
Flow Cytometry
Flow cytometric analysis is based on an antigen-antibody reaction with fluorochrome-
conjugated antibodies. Combined with information about granularity and size of mi-
croscopically small particles, such as cells, cell types can be easily identified by their
individual expression of surface molecules.
Flow cytometry was used to determine the expression of surface molecules on multiple
cell lines. Furthermore, the total number of leukemic blasts in a flow cytometry based
kill assay was measured. Finally, the expression of activation molecules on T cells after
stimulation with a bispecific antibody was determined.
Flow Cytometric Staining of Surface Molecules
To determine the expression of surface molecules on multiple cell lines, flow cytometric
staining was performed.
Cells were harvested as described above, and adjusted to a concentration of 106 per ml.
200 µl of the cell suspension was plated in a 96-well plate. Subsequently, the cells were
centrifuged for three minutes at 561× g and the supernatant was discarded. The cell pellet
was washed by resuspending in 200 µl of FACS buffer, and centrifuging for three minutes
at 561 × g. The washing step was repeated one more time. Murine antibodies directed
against surface molecules were diluted in FACS buffer and adjusted to a concentration of 5
µg/ml. 50 µl of the antibody dilution was added per well. The cell pellet was resuspended
38
2.2 Methods
and the plate was kept in the dark at 4 °C for 30 minutes. Afterwards, the plate was
centrifuged at 561 × g for three minutes, and the supernatant was discarded. Next, the
cells were washed twice. Goat anti-mouse PE conjugated antibodies were diluted 1:200
in FACS buffer. 50 µl of the dilution was added to each well. The cell pellets were
resuspended and the plate was kept in the dark at 4 °C for 25 minutes. Afterwards, the
plate was centrifuged at 561 × g for three minutes and the supernatant was discarded.
Next, the cells were washed twice and the cell pellet was resuspended in 250 µl of FACS
buffer. FACS analysis was performed with a FACSCalibur.
Flow Cytometry Based Activation Assay
Flow cytometry was used to determine the expression of activation molecules on T cells
after stimulation with a BsMAb.
Blood was drawn from healthy donors and PBMCs were isolated, as described pre-
viously. PBMCs were adjusted to a concentration of 3 × 106/ml in RPMI Complete
Medium, and plated in a 96-well plate. BsMAb and monospecific blocking antibodies
were diluted in RPMI Complete Medium and 50 µl of the dilution was added per well.
The plate was kept in a humidified atmosphere at 37 °C and 5% CO2. After two days of
incubation, the cells were centrifuged for three minutes at 561 × g, and the supernatant
was discarded. In order to wash the cells, the cell pellet was resuspended in 200 µl of
FACS buffer and centrifuged for three minutes at 561 × g. The washing step was re-
peated one more time. Conjugated murine anti-human antibodies directed against CD4,
CD8, CD45 and CD69 were adjusted to a concentration of 5 µg/ml in FACS buffer and
added to the cells. The cell pellet was suspended in 50 µl of the antibody dilution and
kept in the dark at 4 °C for 30 minutes. The plate was then centrifuged at 561 × g for
three minutes, and the supernatant was discarded. Next, the washing step was carried
out twice. A solution containing 12 µl 7AAD viability staining solution per ml FACS
buffer was added ten minutes prior to the start of the FACS analysis. FACS analysis was
performed with a FACSCanto.
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Flow Cytometry Based Kill Assay
Flow cytometry was used to determine the exact number of leukemic blasts in a kill assay
using autologous immune cells from patients. Additionally, T cell proliferation, and the
expression of activation markers on T cells could be measured.
Blood was drawn from leukemia patients and PBMCs, including leukemic blasts, were
isolated as described previously. 500,000 PBMCs, including leukemic blasts, were plated
per well in a 96-well plate. BsMAb and monospecific blocking antibodies were diluted in
RPMI Complete Medium and 50 µl of the dilution was added per well. The plate was kept
in a humidified atmosphere at 37 °C and 5% CO2. After three days of incubation, the
cells were centrifuged for three minutes at 561× g, and the supernatant was discarded. To
wash the cells, the cell pellet was resuspended in 200 µl of FACS buffer and centrifuged
for three minutes at 561 × g. The washing step was repeated one more time. Conjugated
mouse anti-human antibodies were adjusted to a concentration of 5 µg/ml in FACS buffer.
The cell pellet was suspended in 50 µl of the antibody dilution, and kept in the dark at 4
°C for 30 minutes. Afterwards, the plate was centrifuged at 561× g for three minutes, and
the supernatant was discarded. Next, the washing step was performed twice. A solution
for viability staining and standardization was prepared, containing 12µl 7AAD Viability
staining solution and two drops of BD negative beads per ml FACS buffer. FACS analysis
was performed with a FACSCanto.
ELISA (Enzyme-Linked Immunosorbent Assay)
Cytokine ELISAs were performed to assess the production of IFNγ by activated T cells
after stimulation with a bispecific antibody. An ELISA allows the quantification of cy-
tokines in cell culture or assay supernatant. The antigen to be measured can be detected
by two non-cross-reacting antibodies. First, the antigen binds to the capture antibody,
which is bound to a microtitre plate, the detection antibody then binds to the antigen. The
total amount of bound detection antibody correlates with the amount of antigen. In or-
der to determine the amount of antigen, the detection antibody is conjugated with biotin,
which forms a stable complex with streptavidin. Streptavidin is added afterwards, and is
conjugated with peroxidase, an enzyme that can convert a substrate added later. The con-
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version of the substrate is determined by a change of color, which can be measured using
a photometer. In fact, the extinction correlates with the total amount of bound antigen. In
order to determine the absolute amount of IFNγ, a standard curve was added to the test
samples.
First, 96-well Maxisorp plates were coated with the capture antibody. To this end, the
coating antibody was adjusted to a concentration of 1 µg/ml. 50 µl of the dilution was
plated per well. The plate was covered with a sealer and incubated overnight at 4 °C.
The next day, the microtitre plates were washed five times with a washing buffer and
thereafter loaded with 200 µl blocking buffer, and then incubated for one hour at room
temperature. After the washing procedure, standards and samples were diluted 1:2 and 50
µl of each was transferred into the wells in triplicate, and incubated for one hour at room
temperature.
A serial dilution of recombinant IFNγ served as the standard, whereas supernatants
from the proliferation assays were the test samples. After the washing step, a biotinylated
antibody was adjusted to a concentration of 1µg/ml and 50µl was plated per well. The
incubation period of one hour at room temperature was followed by a washing step. Next,
streptabidin-HRP conjugate was diluted 1:5000, and 50 µl of the dilution was transferred
to each well. After the incubation for 30 minutes at room temperature, the washing step
was performed again. Eventually, 50µl of substrate solution was added per well. After
a short incubation period in the dark, enzymatic color development was confirmed. The
enzymatic process was immediately stopped by adding 50µl stop solution. The specific
extinction was measured using a SpectraMax 340 ELISA reader.
2.2.3 Functional Immunological Assays
XCELLigence Assay
XCELLigence assays were performed to observe real-time killing of adherent tumor cells
by PBMCs in the presence of BsMAb, and blocking reagents.
Adherent tumor cells (22RV1) were harvested as described previously, and adjusted
to a concentration of 1 × 106 per ml. 50 µl of RPMI 1640 Complete Medium per well
was plated in an E-Plate 96. The plate was installed in a RTCA XCELLigence System
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in an atmosphere of 37 °C, 5% CO2 and 90% humidity. Afterwards, 50 µl of the cell
suspension was seeded onto the E-plate to reach a total cell number of 50,000 per well.
The plate was installed in the reader and kept for 20 hours in the atmosphere described
above. Measurement of cell indices was performed every 15 minutes. Cell indices are an
indicator of the total number of viable adherent cells, as killing and subsequent detach-
ment of tumor cells results in lower cell indices. After the first incubation period, PBMCs
and different antibodies were plated. The whole assay was incubated for approximately
four days, and cell indices were determined every 15 minutes.
[methyl-3H] Thymidine Activation Assays
Cell proliferation was measured as an indicator of the activation of T cells. To deter-
mine the proliferation of T cells, the incorporation of [methyl-3H] thymidine into newly
synthesized DNA was measured.
To this end, human PBMCs were isolated as described above, adjusted to a concentra-
tion of 2 × 106 per ml in RPMI 1640 complete medium, and pipetted at a concentration
of 100,000 per well in a 96-well flat bottom plate. Then, 100,000 of either irradiated
target cells or SBCs were added per well. Finally, BsMab at a concentration of 1 µg/ml
and monoclonal blocking antibodies at a concentration of 1 µg/ml were added. The assay
was incubated for approximately 48 hours at 37 °C, 7.5% CO2 and 90% humidity. Af-
terwards, the cells were pulsed with 0.5 µCi per well of [methyl-3H] thymidine. This was
followed by a further incubation of approximately 16 hours. The mixture was then har-
vested with the cell harvester on Printet Filtermat A mats. Only incorporated thymidine
binds to the mats, whereas non-incorporated thymidine does not. Next, the filter mats
were dried at 50 °C for 30 minutes. The level of radioactive DNA was determined after
addition of a scintillation fluid, using the MicroBeta2 scintillation.
Adhesion Assay
Lymphocyte adhesion assays were performed in 24-well culture plates. HUVECs were
seeded at a concentration of 50,000 per square centimeter in Endothelial Cell Growth
Medium and cultivated for two days. Formation of a HUVEC monolayer was confirmed
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by microscopy. Afterwards, HUVECS were washed twice with 1000 µl of RPMI Com-
plete Medium. PBMCs were isolated as described above, and adjusted to a concentration
of 500,000 per ml. They were then stimulated with a BsMAb at a concentration of 1
µg/ml for one hour. Then, 2500 µl of the PBMC suspension was plated into the 24-well
plates. Immediately afterwards, blocking antibodies were added at a concentration of 1
µg/ml. After an incubation of three hours, non-adherent cells were removed by washing
with 1000 µl RPMI Complete Medium three times. next, adherent cells were detached
by addition of Accutase detachment solution. HUVECs and adherent PBMCs were col-
lected, and flow cytometry was performed to determine the absolute numbers of adhering
CD45+ cells.
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3 Results
3.1 The ability of T cell-activating bispecific
antibodies to induce off-target activation
It is widely held, that BsMAb work in a target cell-restricted manner, thus limiting the T
cell effector functions to the site of cells that express the tumor-associated antigen (TAA)
that the antibody is directed against. Binding of the anti-CD3 arm to T cells is thought not
to induce any T cell activation in the absence of target cells. However, off-target T cell
activation, especially in the blood, could explain various side effects seen with BsMAb.
The activation assays in this work were conducted using PBMCs, isolated from peripheral
blood, and a BsMAb termed NP-CU, which is composed of a binding site to PSMA, an
antigen that is not present on PBMCs, and the aCD3 antibody UCHT1.
3.1.1 [methyl-3H] Thymidine activation assays
To determine the ability of the bispecific PSMA×CD3 antibody NP-CU to induce off-
target T cell proliferation, thymidine uptake assays were performed. 100,000 freshly iso-
lated PBMCs per well in a 96-well plate were cocultivated with NP-CU at a concentration
of 1 µg/ml for three days.
The results show that the PSMA×CD3 antibody is capable of inducing moderate T cell
proliferation in the absence of target cells. This suggests that a monovalent CD3 stimulus
can lead to some T cell activation. This particular effect is dose-dependent and could
be reproduced using PBMCs from 12 healthy donors. The required minimum dose to
generate this effect is around 300 ng/ml.
An average proliferation of 10% of the maximum was observed, with phytohemagglu-
tinin (PHA) at a concentration of 10 µg/ml defining 100% activation. PBMCs alone do
not show any significant thymidine uptake. (Fig. 3.1)
Off-target induced T cell activation was also induced by other TAA×CD3 BsMAb than
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NP-CU. A bispecific chondroitin sulfate proteoglycan 4 (CSPG4) × CD3 antibody was
capable of inducing similar T cell activation in an TAA− environment. (Data not shown)
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Figure 3.1: T cell proliferation in response to off-target activation with the BsMAb NP-CU
Freshly isolated PBMCs from a healthy donor were cocultivated with a PSMA×CD3 antibody at a
concentration of 1µg/ml for two plus one days and T cell proliferation was assessed using a thymidine
incorporation assay. A The experiment was repeated 12 times using PBMCs from different healthy
donors. B Concentration dependency of this effect. Representative results from one out of three ex-
periments with PBMCs from different healthy donors are shown. Each data point represents the mean
value of triplicate samples.
3.1.2 FACS-based activation assays
CD69 is a well-established early activation marker on both natural killer cells and T cells.
The following experiments addressed the expression of CD69 on T cells after monovalent
CD3 stimulation with NP-CU, independent of target cells. 100,000 freshly harvested
PBMCs and BsMAb at a concentration of 1 µg/ml were cultured for 48 hours. Then, the
CD69 expression on CD4+ and CD8+ T cells was assessed using flow cytometry.
The results show that a monovalent CD3 stimulus can induce expression of CD69 on
both CD4+ and CD8+ T cells. After stimulation with either NP-CU or a CSPG4×CD3
antibody at a concentration of 100 ng/ml, 20% of the CD4+ T cells and 15% of all CD8
+ T cells expressed CD69 (Fig. 3.2). A CD19×CD3 antibody induced CD69 expression
in 60% - 70% of all T cells due to on-target activation by CD19+ B cells. A FLT3×CD3
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Figure 3.2: CD69 expression on T cells after off-target stimulation with different BsMAb PBMCs
were incubated with PSMA×CD3 or CSPG4×CD3 bispecific antibodies at a concentration of 100
ng/ml for 48 hours. After that, CD69 expression on T cells was assessed via flow cytometry. A T
cells were defined as CD45+, CD8+ or CD4+. B CD19xCD3 or FLT3xCD3 antibodies served as
positive controls. All tests were performed in triplicates. C Representative results from one out of
three experiments with PBMCs from different healthy donors are shown.
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BsMAb induced CD69 expression in 40% of all cells. FLT3 is present on monocytes at a
small amount compared with CD19 on B cells. These findings confirm that monovalent
CD3 stimulation by BsMAb induces activation of T cells and subsequent expression of
CD69/IL-2 receptor. In comparison with the thymidine uptake assays, the flow cytometry-
based activation assays seem to be more sensitive, as the BsMAb induced T cell activation
at a concentration as low as 100ng/ml.
3.2 Identification of stimulating bystander cells
As lymphocyte adhesion to vascular endothelial cells happens rapidly after administration
of BsMAb, it is likely that these cells amplify off-target activation by BsMAb. Lymphoid
cells within the lymph nodes could induce similar effects. The following experiments
addressed the influence of certain lymphoid and endothelial cells on the induction of
off-target activation. As a first step, flow cytometric surface staining of various cancer
cell lines was performed to rule out expression of PSMA or CSPG4 on these potential
bystander cells. To investigate further, whether SKW6.4, JY, and NALM-16 lymphoid
cells, and HUVECs amplify off-target T cell activation, thymidine uptake assays were
conducted.
It was shown that some lymphoid cell lines, such as SKW6.4 and JY, are capable of
enhancing the activation of T cells by BsMAb, while others fail to do so (Fig. 3.3). Thus,
the stimulating cells will be referred to as stimulating bystander cells (SBCs).
However, not all lymphoid cell lines tested could be characterized as SBCs. NALM-
16 cells, derived from an acute precursor B cell leukemia, showed no enhancement of
off-target T cell activation.
To rule out any allogeneic effects, several other tumor cell lines were tested for stim-
ulating properties in an off-target setting. It was shown that neither LN-18 glioblastoma
cells, nor SKMel melanoma cells are capable of enhancing off-target activation.
HUVECs are a widely accepted model of endothelial cells. As endothelial cells are
most likely involved in BsMAb-induced leukocyte adhesion and activation, they were
tested for stimulating properties as described above. The results show that HUVECs are
able to enhance off-target activation markedly. However, off-target activation triggered
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Figure 3.3: Stimulating properties of different cell lines A Different lymphoid cells (SKW6.4, JY,
NALM-16), glioblastoma cells (LN-18), melanoma cells (SKMel) and human umbilical vein endothe-
lial cells (HUVECs) were either cultivated alone (depicted as C), together with PBMCs (depicted as
C+P), or with PBMCs and a PSMA×CD3 BsMAb (NP-CU) at a concentration of 1 µg/ml (depicted
as C+P+BsMAb), or with PBMCs and a monoclonal CD3 antibody (UCHT1) at a concentration of 1
µg/ml (depicted as C+P+aCD3) for three days and incorporated thymidine was determined. The effec-
tor:target ratio was 1:1 with 100,000 cells per well. Cell lines were evaluated as stimulating (depicted
as +) or non-stimulating (depicted as -). B The experiment was repeated ten times using PBMCs from
different healthy donors. Each data point represents the mean value of triplicate samples derived from
one individual.
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by HUVECs is slightly less pronounced than that obtained by JY or SKW6.4 cells.
3.3 The mechanism of off-target activation
Table 3.1: Expression of costimulatory molecules on cell lines Flow cytometric expression analysis
was performed as described in the material&methods section. Strong expression (depicted as +), weak
expression (depicted as (+)) and absence of the molecule (depicted as -) was distinguished.
Molecule HUVEC NALM-16 SKW6.4
CD54 (ICAM-1) (+) + +
CD102 (ICAM-2) + + +
CD80 - - +
CD86 - - +
CD252 (OX-40L) (+) (+) (+)
CD137L (4-1BB) - - +
CD275 (LICOS) + + +
CD62E (E-Selectin) - - -
CD62L (L-Selectin) - - +
CD40 + - +
CD58(LFA-3) + + +
The following experiments were conducted to address the influence of costimulatory
molecules on SBCs during the induction of off-target activation.
As a first step, expression of costimulatory molecules on stimulating cells was com-
pared with the expression on nonstimulating bystander cells via flow cytometry.
To this end, SKW6.4 cells and HUVECs (stimulating) were compared with NALM-16
cells (non-stimulating).
The results are depicted in Table 1.1.
It could be shown that the stimulating cell line SKW6.4 expresses a greater variety of
costimulatory molecules than NALM-16, which is characterized as nonstimulating. It is
further remarkable that HUVECs only show a weak expression of CD54.
Nevertheless, CD40 was the only costimulatory molecule tested, which is present on
stimulating cell lines, but not on non-stimulating cells.
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3.4 Inhibition of off-target activation by blocking
antibodies and steroids
In the previous experiments, it was shown that SBCs bearing a variety of costimulatory
molecules enhance BsMAb-induced off-target T cell activation. The following experi-
ments were conducted to block costimulatory molecules on SBCs with various antibod-
ies. For this purpose, [methyl-3H] thymidine uptake assays with blocking antibodies in
comparison with steroids were performed.
3.4.1 [methyl-3H] Thymidine activation assays
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Figure 3.4: Inhibition of off-target T cell activation in the presence of SKW6.4 Freshly isolated
PBMCs from healthy donors and SKW6.4 cells were cocultivated with both a PSMA×CD3 antibody
and a blocking antibody at a concentration of 1 µg/ml or a steroid at a concentration of 10 µg/ml for
three days. Then, incorporated thymidine was determined. PBMCs incubated with SKW6.4 and NP-
CU at a concentration of 1 µg/ml were used as reference. Representative data from one out of three
experiments are shown. Mean values and standard deviations of triplicate samples are indicated.
Off-target T cell activation induced by BsMAb in the presence of SBC SKW6.4 could
be reduced by different agents. However, one should note that, in all cases, blocking
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activity of the respective antibodies has not been confirmed in separate independent ex-
periments.
Although blocking antibodies directed against the established costimulatory molecules
CD80 and CD86 had no effect, antibodies directed to LICOS or the adhesion molecules
ICAM-1 (CD54), LFA-3 (CD2), or LFA-1 (CD18) exerted a variable blocking effect,
the one induced by the anti-CD18 antibody being most pronounced, reaching almost
complete inhibition, comparable to that achieved by prednisolone at a concentration of
10µg/ml.
In a next step, an anti-TNFα antibody was also assessed. It was shown that off-target
T cell activation by BsMAb in the presence of SKW6.4 is not affected by this antibody.
Fig 3.4 summarizes the results.
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Figure 3.5: Inhibition of off-target T cell activation in the presence of HUVECs Freshly isolated
PBMCs from healthy donors and HUVECs were cocultivated with both a PSMA×CD3 antibody and
a blocking antibody at a concentration of 1 µg/ml or a steroid at a concentration of 10 µg/ml for three
days. Incorporated thymidine was determined afterwards. PBMCs incubated with SKW6.4 and NP-
CU at a concentration of 1 µg/ml were used as reference. Representative data from one out of three
experiments are shown. Mean values and standard deviations of triplicate samples are indicated.
Similar results were obtained, when HUVECs were used as SBCs instead of SKW6.4
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3.4 Inhibition of off-target activation by blocking antibodies and steroids
cells (Fig. 3.5). Again, CD18 blockade and prednisolone were most effective. In contrast
to the experiments conducted with SKW6.4, TNFα blockade seems to reduce off-target
T cell activation triggered by HUVECs to some extent.
However,blocking of CD40, which is the only costimulatory molecule that is expressed
on stimulating, but not on nonstimulating cells, showed no effect.
The results observed during off-target blocking assay suggest that different costimula-
tory and adhesion molecules amplify off-target activation.
3.4.2 FACS-based activation assays
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Figure 3.6: Inhibition of CD69 expression after off-target activation PBMCs from a healthy
donor were incubated either with a PSMA×CD3 BsMAb at a concentration of 1µg/ml (depicted as
P+BsMAb), or together with HUVECs and a BsMAb (depicted as P+H+BsMAb) in the presence or
absence of blocking reagents at a concentration of 1 µg/ml. After 48 hours, CD69 expression on T
cells was assessed via flow cytometry. Representative results from one out of three experiments with
PBMCs from different healthy donors are shown.
Flow cytometry-based activation assays were performed to investigate whether some
of the identified blocking reagents are capable of reducing CD69 expression on T cells
after off-target activation in the presence and absence of SBCs. For this purpose, aCD18
antibodies as well as TNFα blockers and prednisolone were assessed.
Addition of a BsMAb to PBMCs induced CD69 expression in approximately 50% of
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all T cells. Antibody-mediated blocking of CD18 as well as application of prednisolone
brought CD69 expression on both CD8+ and CD4+ T cells down to the baseline level,
with the inhibition induced by prednisolone being slightly pronounced regarding CD4+
T cells. Addition of aTNFα antibodies almost completely blocked off-target T cell acti-
vation in the absence, but not in the presence of HUVECs. One should note that aTNFα
antibodies can effectively block T cell proliferation in a thymidine incorporation assay,
but fail to inhibit CD69 expression on T cells (Fig. 3.6).
3.4.3 IFNγ ELISA
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Figure 3.7: Inhibition of off-target induced IFNγ release PBMCs (P) from a healthy donor were
incubated with HUVECs (H), a PSMA×CD3 BsMAb at a concentration of 1ug/ml and different block-
ing antibodies at a concentration of 1 µg/ml for 48 hours. After that, IFNγ release was determined by
an ELISA. Mean values of triplicate samples are indicated.
IFNγ is an important pro-inflammatory cytokine. Distribution of IFNγ is an indicator
of the activation of both innate and adaptive immune cells.
To determine whether off-target T cell activation induces IFNγ release, enzyme-linked
immunosorbent assays (ELISAs) were performed. Therefore, supernatants from two-
day activation assays with PBMCs, HUVECs and BsMAb were analyzed. It was further
investigated, whether blocking agents such as aCD18 antibodies, aCD54 antibodies, and
aTNFα antibodies reduce IFNγ release after off-target stimulation.
The experiments showed that off-target T cell activation triggered by BsMAb in the
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presence of HUVECs induces IFNγ release of 6 pg/ml. Addition of aCD54 antibodies
and a CD18 antibodies could reduce the release by 50% and 80%, respectively. While off-
target activation was only reduced by 50% in the presence of antibodies against TNFα,
they completely blocked IFNγ production by immune cells (Fig. 3.7).
In summary, these experiments showed that antibodies against CD18, CD54, CD2, and
TNFα, as well as prednisolone are capable of reducing off-target T cell activation, thus
preventing proliferation, CD69 expression and cytokine release, with an aCD18 antibody
being the most effective blocking reagent.
3.5 The impact of blockade on on-target activation
A possible blocking reagent for the clinical application should not interfere with the
BsMAb-mediated on-target T cell activation, which is necessary for anti-tumor effects.
The following experiments were performed to assess, whether blockade of leukocyte anti-
gens or cytokines will impair on-target activation of T cells mediated by BsMAb. To this
end, the previously identified antibodies against CD18, CD54, CD2, and TNFα were
tested in comparison with prednisolone, in the presence of target cells to which BsMAb
bind.
3.5.1 [methyl-3H] Thymidine activation assays
For this purpose, four different constellations of BsMAb and target cells were analyzed.
CD19+ SKW6.4 cells, FLT3+ NALM-16 cells, Endoglin+ HUVECs, and PSMA+ 22RV1
cells were incubated with the respective BsMAb, and thymidine incorporation assays
were performed.
The results showed that neither blockade of CD18 or CD11a on T cells, nor CD54
on target cells impair T cell proliferation in any of the four described constellations. In
contrast, TNFα blockade could be shown to reduce on-target T cell activation by 0 to
40%. Notably, blockade of CD2 led to a reduction of on-target activation by 30 to 50%.
Prednisolone almost completely blocked any T cell activation triggered by a TAA× CD3
BsMAb and TAA+ cells (Fig. 3.8).
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Figure 3.8: Inhibition of BsMAb-induced on-target T cell activation Freshly isolated PBMCs
from healthy donors were cocultivated with TAA+ cells and corresponding TAA×CD3 BsMAb at a
concentration of 1 µg/ml and different blocking reagents at a concentration of 1 µg/ml for two plus
one days and incorporated radioactivity was determined. A FLT3+ NALM-16 + FLT3×CD3 B
CD19+ SKW6.4 + CD19×CD3 C PSMA+ 22RV1 + PSMA×CD3 D Endoglin+ HUVECs
+ Endoglin×CD3. Representative results from one out of three experiments with PBMCs from differ-
ent donors are shown.
3.5.2 FACS-based lysis assay
The following lysis assay was performed to examine whether blocking agents interfere
with the killing of leukemic blasts by autologous immune cells. PBMCs containing
leukemic blasts were drawn from a leukemia patient and cocultivated with a FLT3xCD3
antibody and several blocking agents for 72 hours. FACS analysis was performed to de-
termine reduction of the blast portion and T cell activation. As this assay is conducted
using autologous immune cells and leukemic blasts, the experiment is as close as possible
to in vivo conditions during clinical application.
It was shown that a FLT3 × CD3 antibody is capable of reducing the percentage of
leukemic blasts in human PBMCs. After three days, the blast portion was reduced from
50% to 10%. The required dose to yield this effect is about 20 ng/ml. A PSMA × CD3
BsMAb served as the negative control and was not capable of inducing killing of tumor
cells.
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Figure 3.9: Impairment of the killing of leukemia cells by autologous immune cells 500,000
PBMCs including leukemic blasts were drawn from a patient and cocultivated with a FLT3xCD3 anti-
body at a concentration of 1µg/ml and several blocking agents for 72 hours. After that, FACS analysis
was performed using beads to determine absolute cell numbers. A Leukemic blasts were defined as
CD45dim, CD33+, CD117+. B&C CD69 expression on T cells. Representative results from one out
of two experiments with PBMCs from different patients are shown.
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In the next step, different blocking reagents were tested for kill-inhibiting properties.
Notably, blockade of CD18 on T cells impaired tumor cell killing, but did not lead to a
reduced expression of CD69 on T cells. Addition of aTNFα antibodies did neither impair
killing of leukemic blasts nor CD69 expression in this assay, whereas prednisolone caused
a complete blocking of BsMAb-induced tumor cell killing and CD69 expression on T cells
(Fig. 3.9).
3.5.3 IFNγ ELISA
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Figure 3.10: Inhibition of on-target induced IFNγ release PBMCs from a healthy donor were incu-
bated with Endoglin+ HUVECs, a Endoglin×CD3 BsMAb at a concentration of 1ug/ml and different
blocking antibodies at a concentration of 1µg/ml for 48 hours. After that, IFNγ release was determined
using an ELISA. Mean values of triplicate samples are indicated.
The following ELISA was conducted to assess, whether different blocking reagents
reduce the desired IFNγ release that was induced by BsMAb-triggered on-target T cell
activation.
The results showed that incubation of PBMCs together with Endoglin+ HUVECs and
an Endoglin×CD3 antibody led to a release of IFNγ at a concentration of 600 ng/ml. Ad-
dition of aCD54 antibodies impaired IFNγ release only slightly. In contrast, aCD18 anti-
bodies reduced IFNγ release by almost 50%, and addition of aTNFα antibodies blocked
IFNγ distribution completely (Fig. 3.10).
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3.5.4 XCELLigence lysis assays
XCELLigence assays are impedance-based lysis assays that allow real-time assessment
of lysis of adhering tumor cells by immune cells. Adherent tumor cells were seeded in a
96-well E-Plate and cultivated for 20 hours. Then, PBMCs and antibodies were added.
Assessment of cell indices (viable tumor cells) was performed every 15 minutes for 96
hours.
The following experiment was conducted to assess, if different blocking reagents im-
pair killing of PSMA+ 22RV1 cells by T cells in the presence of a PSMA×CD3 BsMAb.
It was shown that neither aCD18 antibodies nor aTNFα antibodies inhibit lysis of tu-
mor cells in an XCELLigence assay. In contrast, prednisolone almost completely blocks
killing of the tumor cells (Fig. 3.11).
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Figure 3.11: Real-time assessment of tumor cell death mediated by BsMAb 22RV1(PSMA+) ad-
herent tumor cells were seeded in a 96-well E-Plate and cultivated for 20 hours. Then, PBMCs and a
PSMA×CD3 BsMAb as well as different blocking reagents were added at a concentration of 1 µg/ml.
Assessment of cell indices (viable tumor cells) was performed every 15 minutes for ca. 96 hours. Each
curve represents the mean value of triplicate samples.
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3.5.5 Target-cell dependency of on-target blockade
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Figure 3.12: On-target blockade in the presence of varius amounts of target cells 100,000 freshly
isolated PBMCs from healthy donors were cocultivated with different numbers of CD19+ SKW6.4
cells and a CD19×CD3 antibody at a concentration of 1 µg/ml for two plus one days. 50% of all
samples contained an aCD18 antibody at a concentration of 1µg/ml. Incorporated thymidine was
determined. Phytohemagglutinin (PHA) at a concentration of 10 mg/ml was used as a positive control.
Mean values and standard deviations of triplicate samples are indicated.
In the following experiment, the target-cell dependence of on-target impairment was
assessed. For this purpose, thymidine incorporation assays were performed using 100,000
PBMCs and differing numbers of CD19+ SKW6.4 cells, a CD19×CD3 BsMAb, and an
aCD18 antibody. It could be shown that CD18 blockade impairs on-target activation only
at E:T ratios above 3:1. At lower ratios, e.g., 2:1, no blockade of on-target activation
could be observed (Fig. 3.12).
In summary, aCD18 and aTNFα antibodies impaired tumor cell killing in different
experimental settings only slightly, with the reduction of tumor cell killing by aCD18
antibodies being most pronounced in a FACS-based lysis assay. Anti-CD2 antibodies and
prednisolone showed significant reduction of both on-target T cell activation and tumor
cell killing, which are undesired effects upon clinical application.
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3.6 Induction of leukocyte adhesion through
off-target stimulation
3.6.1 Adhesion assay
The following experiments addressed the induction of leukocyte adhesion through off-
target stimulation by BsMAb and the underlying mechanisms. To this end, an adhesion
assay was established.
Freshly isolated PBMCs were stimulated with a PSMA×CD3 antibody and plated on a
HUVEC monolayer together with blocking antibodies. After an incubation of three hours,
the number of adhering CD45+ lymphocytes was determined.
The results suggest that a bispecific PSMA×CD3 antibody is capable of inducing T cell
adhesion to an endothelial cell layer. Antibodies against CD18 could inhibit this adhesion
completely. The resulting adhesion rate was even lower than the spontaneous adhesion of
CD45+ cells to HUVECs. Antibodies directed to CD2 were found to be less effective in
reducing off-target induced T cell adhesion (Fig. 3.13).
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Figure 3.13: Leukocyte adhesion after off-target stimulation Freshly isolated PBMCs were stim-
ulated with a PSMA×CD3 antibody at a concentration of 1µg/ml for one hour. Subsequently, they
were plated on a HUVEC monolayer together with blocking antibodies at a concentration of 1 µg/ml.
After an incubation of three hours, non-adherent cells were removed. HUVECs and adhering cells
were collected and flow cytometry was performed to determine the number of adhering cells.
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4.1 General considerations
Bispecific monoclonal antibodies directed against CD3 mark a very promising class of
therapeutic agents that is able to activate T cells against defined target cells, e.g., tumor
cells. Multiple clinical trials proved the therapeutic efficacy of such molecules, e.g., in
patients suffering from lymphatic leukemia, however at the cost of severe side effects at
rather low antibody doses [J. Tibben et al. 1993] [Kroesen et al. 1994] [Topp et al. 2011].
These include fever, chills, headache, hyperthermia, hypotension, and gastrointestinal
symptoms, which are induced by massive release of cytokines such as TNFα, IFNγ and
IL-2. The cytokine release syndrome occurs only a few minutes after intravenous appli-
cation of the BsMAb, thus suggesting that endothelial cells release cytokines in response
to BsMAb. This effect is considered an off-target activation of the immune system. While
the BsMAb blinatumomab is being activated by CD19+ B cells circulating in the blood,
other BsMAb face a similar problem, even though their target antigen is apparently not
present in the blood stream. These observations suggest that BsMAb are capable of acti-
vating T cells in the absence of target cells at least to some extent, which would explain
the side effects seen with BsMAb. The results presented in this work further support this
hypothesis.
Assuming, that off-target activation plays a major role in the development of cytokine
release syndromes, a better understanding of this phenomenon is of utmost importance.
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4.2 A bispecific PSMA x CD3 antibody is capable of
inducing T cell proliferation due to off-target
stimulation
In this work, it could be shown, that a bispecific PSMA×CD3 antibody, NP-CU, is ca-
pable of inducing T cell activation in the absence of target cells, which resulted in CD69
expression on the T cells, IFNγ release and proliferation. These findings suggest that
every BsMAb with a CD3 binding site faces this problem.
Notably, T cell proliferation in thymidine incorporation assays required the presence
of BsMAb at doses of 300 ng/ml, whereas CD69 expression was induced by BsMAb at a
concentration of 100 ng/ml. These findings suggest that flow cytometry-based activation
assays are more sensitive than thymidine incorporation assays.
The formation of aggregates is a common challenge during the production of "com-
plicated" recombinant molecules, such as BsMAb. Size exclusion chromatography per-
formed by Dipl.-Biol. Fabian Vogt showed no evidence of aggregates after purification of
NP-CU. Thus it is unlikely that aggregates account for the off-target activation observed
in this work. However, further tests for aggregates after a certain storage time should be
performed to rule out any late formation of aggregates.
Another possible source of unspecific T cell activation are endotoxins. Moreover, the
batch of antibody used in this work was shown to contain no significant amount of endo-
toxins, ruling out an endotoxin-induced phenomenon.
4.3 Stimulating bystander cells enhance off-target
activation of T cells
It was demonstrated that certain lymphoid cell lines are capable of enhancing off-target T
cell activation in the presence of BsMAb, but not in the absence of such antibodies. It is
tentative to speculate that in-vivo, cells of the lymph node compartment could exert such
stimulatory activity.
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4.4 The mechanism of off-target activation
Human umbilical vein endothelial cells (HUVECs) have also been shown to augment
off-target T cell activation. The findings in this work are consistent with those presented
by Molema et al. [Molema et al. 2000]. Our findings suggest that BsMAb-coated T
cells in the blood stream are activated by SBCs and thus induce further cytokine release
by immune cells as well as endothelial cells. As endothelial cells are most likely the
first SBCs encountered by BsMAb after application, further research should focus on the
effect of BsMAb on these cells.
The activating properties of SBCs could be shown repeatedly with PBMCs from differ-
ent donors, and various cell types serving as SBCs, such as SKW6.4, JY and HUVECs.
Several other cell lines, e.g., melanoma and glioblastoma cells, did not exhibit such prop-
erties. These results clearly show that the stimulatory effect was not due to allogenic
reactivity.
4.4 The mechanism of off-target activation
The main goal of the subsequent experiments was the identification of costimulatory
molecules on SBCs that enhance off-target activation, in order to eventually diminish
this effect by antagonistic antibodies. CD40 was the only molecule that was shown to
be present on SBCs, but not on non-stimulatory cell lines. However, in blocking experi-
ments, anti-CD40 antibodies failed to exhibit anti-stimulatory properties. The CD40 anti-
body used in this work was characterized as blocking by the supplier Biolegend. However,
the antagonistic properties of the antibody were not confirmed by functional assays. It is
therefore still possible, that CD40 plays an important role in the induction of off-target
activation, a hypothesis that should be tested in additional experiments.
Likewise, all antibodies directed against costimulatory molecules were characterized as
antagonistic by the supplier Biolegend. Thus, the conclusion that not blockable molecules
are not responsible for off-target activation, appears to be valid. However, it should be
noted that the antagonistic properties of the antibodies used in this work have not been
confirmed by own independent functional assays.
ICOS-LICOS interaction was described as a possible cause for dramatic undesired T
cell activation, as observed after application of the CD28 MAb TGN1412 [Weissmüller
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et al. 2012]. In this work, LICOS was found on both stimulating and non-stimulating cell
lines, thus suggesting that this interaction does not play a major role in the induction of
off-target activation by BsMAb.
ICAM-1 (CD54) was found to be present on both stimulating and non-stimulating
cell lines and is known to be the ligand for LFA-1 (CD11a:CD18). ICAM-1 upregula-
tion, however, occurs rapidly after stimulation of endothelial cells with cytokines such as
TNFα. This mode of action could explain the leukopenia as well as the overwhelming
cytokine response after the application of BsMAb [Molema et al. 2000].
4.5 Blocking of defined costimulatory molecules
can reduce off-target activation
From what has been said above, it is likely, that ICAM-1/LFA-1 interaction marks a very
important step in the induction of off-target activation by BsMAb. This is confirmed
by the finding that the most significant reduction of off-target activation was exerted by
antibodies against CD18. In experimental settings with both SKW6.4 and HUVECs, anti-
CD18 antibodies blocked the undesired T cell activation completely. Application of anti-
CD54 antibodies resulted in a reduction of off-target activation that was less pronounced
than that observed with anti-CD18 antibodies.
An important difference between the assays with SKW6.4 and HUVECs as SBCs
is the influence of anti-TNFα antibodies. Off-target activation triggered by HUVECs
was markedly reduced by infliximab, whereas TNFα blockade did not impair SKW6.4-
triggered activation. These findings suggest that both TNFα-dependent and independent
mechanisms are involved in the induction of off-target activation, with endothelial cells
being more susceptible to stimulation by TNFα.
Furthermore, blockade of CD2 could markedly inhibit off-target activation, suggesting
that the interaction of CD2 with CD58 plays a role in the induction of this phenomenon.
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4.6 Inhibition of on-target activation by blocking reagents
4.6 Inhibition of on-target activation by blocking
reagents
Inhibition of off-target activation by blocking agents could diminish the side effects seen
with BsMAb. However, these agents should not impair BsMAb-induced tumor cell killing.
The aim of the subsequent experiments was to test anti-CD18 and anti-CD2 antibodies,
TNFα blockers, and steroids for any suppressive effects on on-target T cell activation
induced by BsMAb in the presence of target cells. To this end, various immunological
assays were conducted.
No impairment of T cell activation and tumor cell killing by anti-CD18 antibodies
was observed in standard experimental settings such as XCELLigence lysis assays and
thymidine incorporation assays. The latter was performed using three different cell lines
and three different BsMAb.
However, the experimental setting that resembles the conditions in-vivo most closely
is a flow cytometry-based lysis assay with PBMCs isolated from leukemic patients. For
example, autologous immune cells and leukemic blasts from a patient at effector-target
ratios « 1 resemble in-vivo conditions of an AML patient suffering from blast crisis. In
this assay, anti-CD18 antibodies reduced T cell activation and tumor cell lysis markedly.
The very low effector target ratios could explain the susceptibility of tumor cell killing to
CD18 blockade in this setting.
Using thymidine incorporation assays, it was shown that the effect of CD18 block-
ade on on-target T cell activation is target cell-dependent: anti-CD18 antibodies block
on-target activation, only if the target antigen is present at a low concentration. This
phenomenon could be clinically relevant, since tumor-associated antigens are often up-
regulated at the tumor site, which means that on-target, but off-tumor activation can be
reduced by this antibody, but not on-tumor activation.
It is evident that the application of prednisolone at rather low doses totally diminished
anti-tumor activity of BsMAb-triggered T cells. These findings are not consistent with
the results presented by Brandl et al.. In this publication, prednisolone exerted no nega-
tive influence on tumor cell killing [Brandl et al. 2007]. As corticosteroids are a well-
characterised group of immunosuppressant drugs, it appears likely that these drugs impair
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BsMAb-induced tumor cell killing in-vivo.
A main goal of this work was the identification of antibodies that could replace steroids
as first-choice medication for the prevention of off-target T cell activation. As anti-CD2
antibodies effectively impaired on-target T cell activation, they do not appear suitable as
a possible medication for the prevention of off-target activation. In contrast, anti-TNFα
antibodies as well as anti-CD18 antibodies showed no significant impairment of tumor
cell killing in a standard experimental setting, which makes them promising therapeutical
options for the prevention of off-target T cell activation.
4.7 BsMAb-induced off-target activation induces
leukocyte adhesion
Leukopenia in patients that received BsMAb is a phenomenon that could be observed re-
peatedly [Kontermann 2005]. The most likely reason for that is a transient adhesion of
leukocytes to endothelial cells. In preliminary adhesion assays, it could be shown that the
BsMAb NP-CU induces adhesion of CD45+ cells to a layer of HUVECs. As anti-CD18
antibodies were shown to diminish this effect, it is likely that ICAM-1/LFA-1 interaction
plays a major role in the induction of leukocyte adhesion by BsMAb. Further studies
should aim at a better understanding of this phenomenon. It remains an open question
whether ICAM-1/LFA-1 interaction is the first activating step in a chain of signals that
eventually leads to excessive cytokine release, or rather a result of previous cytokine re-
lease by T cells.
4.8 Clinical application of anti-CD18 and anti-TNFα
antibodies
The anti-TNFα antibody used in this work, infliximab, is an authorized pharmaceutical
drug for the treatment of inflammatory bowel disease. Infliximab can be safely applied
and does not cause severe side effects. Off-label use of infliximab should therefore be
considered an option to prevent cytokine release in patients receiving BsMAb.
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4.9 Outlook
In the 1990s, different phase 1 and 2 clinical trials with anti-CD18 antibodies were
conducted, but the antibodies failed to prove their therapeutic potential in the prevention
of myocardial damage following ischemia, hemorrhagic shock and multiple sclerosis.
However, it could be shown that anti-CD18 antibodies can be safely applied in patients,
resulting in sufficient plasma levels [Baran et al. 2001]. The anticipated mode of ac-
tion was the prevention of leukocyte migration towards the site of inflammation in order
to avoid destruction of ischemic tissue. Such antibodies include Rovelizumab (LeukAr-
rest®), developed by Icos, and Erlizumab, developed by Genentech/Roche.
As an anti-CD18 antibody aims at integrin β2, a target that is similar to the target
bound by natalizumab, a specific side effect of natalizumab will be discussed here. Na-
talizumab binds to integrin α4, thus preventing autoreactive T cells from extravasation
and subsequent destruction of myelin sheaths in patients suffering from multiple sclero-
sis. Natalizumab was approved in 2004, but later withdrawn from the market because
of multiple cases of progressive multifocal leukencephalopathy caused by JC virus. The
antibody was later reapproved by the EMA as monotherapy in JC virus negative patients
[Yousry et al. 2006]. Induction of similar side effects by an anti-CD18 antibody appears to
be unlikely. First, the anti-CD18 antibody would only be applied once, as a replacement
for prednisolone, whereas cases of PML attributed to Natalizumab were only observed in
patients that received repeated doses [Bloomgren et al. 2012]. Second, the dosage needed
to prevent cytokine release is most probably lower than the doses applied in the clinical
trials with Natalizumab.
4.9 Outlook
Further research is needed to (1) minimize the off-target properties of BsMAb and (2)
identify therapeuticals that suppress off-target T cell activation and subsequent cytokine
release, without affecting the desired on-target activity.
Minimization of off-target activation by BsMAb should include complete humanization
of therapeutic BsMAbs, characterization of different antibody formats regarding off-target
activation, including the use of various CD3-binding epitopes such as OKT3, UCHT-1,
and others.
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In this work, anti-CD18 antibodies as well as anti-TNFα antibodies were characterized
as promising agents for the prevention of off-target T cell activation. In-vivo studies are
necessary to further confirm the blocking properties of these agents. Possible experimen-
tal designs include the use of CD18 knockout mice.
The data presented in this work suggests that CD18 knockout mice are less suscepti-
ble to off-target T cell activation. Thus, in-vivo studies could be conducted to find out,
whether the respective blocking agents impair tumor cell killing or extravasation of im-
mune cells at the tumor site.
An alternative would be the use of surrogate antibodies containing a CD3 antibody,
which is reactive with the mouse molecule. Those reagents, and in particular their specific
side effects, could be then studied in immunocompetent mice.
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Summary
Recently, bispecific monoclonal antibodies (BsMAb) yielded promising results regarding
the treatment of various malignant diseases. However, the serum levels that can be safely
achieved in humans remain suboptimal in terms of saturation of the tumor-associated
antigen (TAA), as the application of higher doses results in systemic cytokine release
and transient leukopenia. Off-target activation of circulating immune cells, stimulated by
the BsMAb, could explain most of the side effects observed after in-vivo application of
BsMAb.
In this work, immunoassays were conducted, which showed that BsMAb are capa-
ble of inducing T cell proliferation in the absence of target cells. Furthermore, it was
demonstrated that human umbilical vein endothelial cells (HUVECs) as well as various
lymphoid cell lines markedly amplify this effect. They are acting as stimulating bystander
cells (SBCs). Several lymphoid and non-lymphoid cell lines did not exhibit this property,
thus ruling out allogeneic effects.
Functional assays were conducted to characterize blocking antibodies directed against
costimulatory and adhesion molecules on both stimulating bystander cells and immune
cells, that are capable of reducing off-target activation. Antibodies against CD54, CD2,
and TNFα reduced off-target activation markedly, whereas antibodies directed against
CD18 as well as prednisolone blocked it completely.
Further experiments addressed the effect of blocking reagents on the induction of on-
target activation and subsequent killing of tumor cells by T cells after stimulation with
BsMAb. Prednisolone and aCD2 antibodies impaired tumor cell killing markedly, while
only minor reduction was observed with aCD18 and aTNFα antibodies.
Using an adhesion assay, it was shown that PBMCs adhere to a HUVEC layer to a
higher extent when stimulated with BsMAb compared to unstimulated PBMCs. Antibod-
ies directed against CD18 could greatly reduce this phenomenon.
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In summary, aCD18 and aTNFα antbodies appear to be promising agents for the pre-
vention of cytokine release after application of BsMAb. Eventually, they could replace
prednisolone as first line drug, since prednisolone exerted a pronounced inhibition of
BsMAb-induced tumor cell killing. However, further in-vivo assays need to be conducted
to further characterize the blocking properties of aCD18 and aTNFα blocking antibodies
and possible side effects, such as a higher susceptibility to infection.
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Zusammenfassung
In den letzten Jahren erzielten bispezifische monoklonale Antikörper (BsMAb) bemerkenswerte
Erfolge in der Behandlung von malignen Erkrankungen. Die in Menschen erreichbaren
Serumkonzentrationen dieser Antikörper sind jedoch nicht ausreichend, um die anvisierten
Tumorantigene (TAA) zu sättigen. Der Grund dafür ist das Auftreten eines Zytokinfreiset-
zungssyndroms und einer transienten Leukopenie. Die Aktivierung von zirkulierenden
Immunzellen durch BsMAb abseits von Tumorzellen würde die meisten Nebeneffekte
erklären, die bisher beobachtet wurden.
In dieser Arbeit wurden Immunassays durchgeführt, die zeigten, dass BsMAb T-Zell-
Proliferation in der Abwesenheit von Zielzellen induzieren können. Außerdem konnte
gezeigt werden, dass humane Nabelschnurvenenendothelzellen (HUVECs) sowie ver-
schiedene lymphatische Zelllinien diesen Effekt verstärken. Deswegen wurden sie im
weiteren als stimulierende Bystanderzellen (SBCs) bezeichnet. Andere lymphatische und
nicht-lymphatische Zellen verstärkten die unspezifische Aktivierung nicht, wodurch ein
rein allogener Effekt ausgeschlossen werden konnte.
Blockierende Antikörper, die gegen bestimmte Zytokine, kostimulierende und Adhä-
sionsmoleküle auf Immunzellen und stimulierenden Nebenzellen gerichtet waren, kon-
nten die unspezifische Aktivierung reduzieren. So konnten Antikörper gegen CD54, CD2
oder TNFα den Effekt deutlich eindämmen. Antikörper gegen CD18 sowie das Steroid
Prednisolon konnten die unspezifische Aktivierung vollständig unterbinden.
Weitere Experimente wurden durchgeführt, um den Einfluss der blockierenden An-
tikörper auf die BsMAb-induzierte T-Zell-Aktivierung, sowie das nachfolgende Killing
von Tumorzellen zu untersuchen. So blockierten Prednisolon und Antikörper gegen CD2
die Aktivierung und Tumorzelllyse vollständig, während Anti-CD18-Antikörper und Anti-
TNFα-Antikörper kaum negative Effekte hatten.
Mittels eines Adhäsionsassays konnte gezeigt werden, dass PBMCs vermehrt an En-
dothelzellen (HUVECs) haften, wenn sie vorher mit BsMAb stimuliert wurden. Dieser
Effekt konnte mit Antikörpern gegen CD18 unterbrochen werden.
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Im Endeffekt stellen Antikörper gegen CD18 und TNFα mögliche Medikamente zur
Verhinderung von Zytokinfreisetzungssyndromen dar. Nach eingehender Charakterisierung
könnten beide Prednisolon als Therapeutikum der Wahl für diese Indikation ersetzen.
Letzteres hatte die Anti-Tumor-Aktivität der T-Zellen in den hier durchgeführten Experi-
menten deutlich eingeschränkt. Nichtsdestotrotz sollten weitere in-vivo Assays durchge-
führt werden, um Antikörper gegen CD18 und TNFα weiter zu charakterisieren und
mögliche Nebenwirkungen zu erkennen, zum Beispiel eine höhere Anfälligkeit für In-
fektionen.
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